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The xenobiotics such as carcinogens, drugs, or pollutants are chemical substances which are
not naturally from human bodies. After entering human bodies, the xenobiotics will
biotransformed into their metabolites by metabolic enzymes, which usually show higher toxicity.
The reactive metabolites react with macromolecules including DNA, proteins, and lipids in cells
to form adducts. During metabolism of xenobiotics, reactive oxygen species (ROS) are also
produced, which would induce oxidative damage on macromolecules. The damaged DNA may
cause mutations during DNA replication. If the mutations occur at critical genes, such as tumor
suppressor gene or oncogenes, this would lead to cancers. The damage on proteins will change
protein functions or provoke an antigen response. One theme of this research is to detect DNA
oxidative damage on tumor suppressor gene by liquid chromatography and mass spectrometry
(LC-MS). The other aim of this research is to develop methods to investigate drug induced protein
damage by LC-MS.
In this thesis, Chapter 2 describes detection of oxidative sites on exon 7 of p53 tumor
suppressor gene induced by catechol and Fenton’s reagent. By comparing our results with p53
database, we correlated these two oxidants with organ specific cancers. Chapter 3 describes an
analytical method to investigate acetaminophen induced glutathione S-transferase adducts.
Different metabolic enzymes were employed to monitor the relative amounts of adducts formation.
Chapter 4 describes a quantitative method for therapeutic monoclonal antibody glycoforms in vivo
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by LC-MS. Overall, this research work has developed analytical methods to detect DNA and
protein damage, which can be used to investigate carcinogen induced genotoxicity and drug
induced toxicity.
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Chapter 1 Introduction
1.1 Goals and Significance
Exposure to reactive endogenous or exogenous chemicals can cause significant DNA and
protein damage in the living cells through the processes of oxidation or adduction. 1 - 3 The
structurally modified DNA bases increase the probability of polymerase errors during DNA
replication. If not repaired, mutations will occur which may lead to cancers.4,5 Modification of a
protein will dysfunction the protein which may lead organ failure.6
One major class of chemical-derived damage to macromolecules is oxidation. Oxidation of
DNA occurs continuously in the human body via reactions with reactive oxygen species (ROS),
e.g., hydroxyl radical (•OH), singlet oxygen (1O2), peroxynitrite (ONOO-), hydrogen peroxide
(H2O2), and superoxide (O2•-). ROS are produced from endogenous processes, like metabolism and
inflammation, and also by exogenous factors, like UV radiation, air pollution, and tobacco smoke.7
Reactive oxygen species (ROS) such as hydroxyl radical, singlet oxygen, peroxynitrite, and
superoxide play important roles in living organisms, e.g. as messengers in cell signaling cascades.
However, they can also induce cell apoptosis during oxidative stress, featuring unregulated
accumulation of ROS from endogenous or exogenous processes. 8 Increasing oxidative DNA
damage levels have been observed in human subject with increase age in coronary heart disease.9,10
Unrepaired oxidative DNA damage can lead to cardiovascular disease, Parkinson’s disease,
Alzheimer’s disease, aging and even cancer.11-15 Oxygen-derived radicals are likely lesions that
induce mutagenesis in hotspot codons in the ras oncogene and the p53 tumor suppressor gene
leading cancers.16-18 (Scheme 1.1)

1

Scheme 1. 1 Pathway of oxidative stress.
Another class of chemical-derived macromolecule damage is drug-induced adduction. One
mechanism of drug-induced hepatotoxicity is irreversible chemical modification of a protein by a
chemically reactive metabolite, which then leads to dysfunction of the protein.6 (Scheme 1.2)
Drug-induced liver injury is the most frequent reason for the withdrawal of an approved drug from
the market. For approved drugs, at supratherapeutic doses or after long-term usage, drugs can also
form reactive metabolites and adduct on proteins.19
The goal of this thesis is to assess the oxidative damage on p53 tumor suppressor gene and
correlate the damage to specific types of cancers; second, to assess the adducted damage on
glutathione S-transferase protein to indicate organ failure by drugs. Chapter 1 introduces the
formation of DNA oxidation and mutations caused by oxidation. The discussion focuses on the
chemistry and biological significance of DNA oxidation. Also, a brief description about protein
modifications by metabolites and post-translational modifications is also discussed. Liquid
chromatography - mass spectrometry (LC-MS) technique on DNA oxidation detection and protein
modification detection is summarized. In Chapter 2, oxidation sites on exon 7 of p53 tumor
suppressor gene caused by catechol/Cu2+/NADPH and Fenton’s reagent is located by LC-MS.
2

Chapter 3 describes a protein damage screening method using magnetic beads bioreactors with
different cytochrome P450 enzymes and LC-MS. Chapter 4 describes a LC-MS quantitative
method for biotherapeutic monoclonal antibody glycoforms in vivo.

Scheme 1. 2 Pathway of Protein adducts formation.
1.2 Oxidation of DNA
1.2.1 ROS
The most common ROS is Hydroxyl Radical (•OH) which can be produced from γ-rays of
60

Co and by Fenton reactions of Fe(II) or Cu(II) ions with hydrogen peroxide.20,21 H2O2 exists in

human cells, Fe(II) ions are physiologically necessary for iron-containing proteins, and Cu(II) ions
exist in blood plasma and cell nuclei. Redox cycling of quinone-like metabolites with Cu(II) and
NADPH can form •OH radical and other ROS. As a simple example, catechol undergoes this type
of redox cycling that leads to a 2 e-oxidation to o-quinone, which subsequently undergoes two 1
electron enzymatic reductions back to catechol (Scheme 1.3). ROS including H2O2, O2•-, and •OH
have been reported and would amplified by the redox cycling.22,23 Thus, •OH radical is generated

3

by multiple sources within human cells, and DNA oxidation by •OH most likely happens
endogenously and exogenously.

Scheme 1. 3 Redox cycling of quinones with M2+ utilizing electrons from NADPH produce
ROS that can oxidize DNA.
Another type of ROS is singlet oxygen (1O2) which is produced during photosensitization
process during which energy is transferred from an excited triplet-state sensitizer to ground-state
oxygen. 24, 25 1O2 can also be produced intracellularly by neutrophils during phagocytosis, and
extracellularly by stimulated macrophages.26,27
Peroxynitrite (ONOO-) is produced by nitric oxide (NO) reacting with superoxide (O2•-) in
vivo, and represents a biologically important oxidant.28,29 It forms under endogenous conditions
and is linked to amyotrophic lateral sclerosis, atherosclerosis, and neurodegeneration. It also forms
from exogenous sources such as tobacco smoke, which contains quinone radicals that reduce
oxygen to O2•- that can react with NO in the smoke to form peroxynitrite.30,31
1.2.2 Oxidation Products
Guanine is the main oxidation target in genes due to having the lowest standard potential (1.3
V vs. NHE) of all native nucleobases32 and is by far the most frequently oxidized DNA base.33,
4

The primary product of guanine oxidation is 8-oxo-7,8-dihydroguanine (8-oxoG), 34 which is a
major biomarker for oxidative DNA damage.35 8-OxoG has a much lower oxidation potential (0.75
V vs. NHE) than guanine, and can be more easily oxidized.36 Considerable effort has been devoted
to identifying the oxidation products of 8-oxoG, and is well accepted that 8-oxoG is not the final
oxidation product of guanine in DNA.37-39 Imidazolone (Iz) was reported as a direct product of
guanine oxidation and can be dehydrated to oxazolone (Ox). Other reported oxidation products of
G include 5-guanidinohydantoin (Gh), spirodihydantoin (Sp), 2,2,4-triaminooxazolone (Oz),
dehydroguanidinohydantoin (DGh), trioxo-[1,3,5]-triazinane-1-carboxamidine (CAC), cyanuric
acid (CA), N-nitro-dehydroguanidinohydantoin (NO2-DGh), parabanic acid (PA), oxaluric acid
(OA), 4-hydroxy-2,5-dioxo-imidazolidine-4-carboxylic acid (HICA), with most resulting from the
initial 8-oxoG.40-42(Scheme 1.4)

Scheme 1. 4 Oxidation products of dG by ROS.
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1.2.3 Mutations
Different oxidation products on DNA may result in different kinds of gene mutations, with
the caveat that occurrence of the mutation depends on the specificity of efficiency of repair of the
targeted gene. During normal DNA replication, guanine pairs with cytosine. If guanine is oxidized
to 8-oxoG, it mispairs with adenine, and thymine pairs with adenine in the next replication, which
leads a G to T transversion.43,44 However, when guanine is oxidized to Iz, it mispairs with guanine,
which leads to a G to C transversion.45 Ox, the hydrolysis product of Iz, gives rise to a G to T
transversion.46,47 Gh causes G to C transversions, Sp stereoisomers cause both G to C and G to T
transversions, depending on the isomeric forms of the oxidation product. 48 If the resulting
mutations are located on critical genes, such as tumor suppressor genes or oncogenes and repair is
not effective, cancers can be promoted.49
1.3 P53 Tumor Suppressor Gene
Tumor suppressor genes encode tumor suppressor proteins that control critical processes, such
as cell growth, cell division, autophagy, and tumor inhibition.50 TP53 (or p53) was confirmed as a
tumor suppressor gene in the 1980s.51 It encodes the p53 protein that regulates cell cycles and
inhibits tumor growth. Unrepaired DNA lesions on p53 would lead to mutations. Mutations in the
p53 tumor suppressor gene are found in 50-60% of human cancers, and some of these correlate
with oxidatively damaged codon sites.52-54 Oxidation products of guanine pair with bases other
than cytosine, which leads to mutations. DNA oxidation by ROS is non-random, and may precede
mutations at the same sites.
Fenton’s reagent induced base pair changes at mutation hot spot p53 codons 248, 249, 250 in
human fibroblasts investigated by restriction fragment length polymorphism/polymerase chain
reaction (RFLP/PCR).55 The DNA sequence containing mutated sites was amplified by PCR. The
6

second G (CGG→CCG) and third G (CGG→CGA) in codons 248 and (AGG→ATG,
AGG→AGT) in codon 249, and the first C (CCC→ACC) in codon 250 was mutated after the
Fenton oxidation.
A yeast reporter system was used to detect change-in-function mutations in p53 gene, which
were caused by DNA oxidation with ROS generated from polycyclic aromatic hydrocarbons (PAH)
o-quinones.56 P53 DNA fragment was incubated with PAH o-quinone and redox cycling system
(NADPH and CuCl2). The yIG397 yeast strain contains an adenine reporter gene under the control
of p21 promoter. A p53-p21 reporter binding assay was used to measure the incidence of mutation.
Then, p53 plasmid DNA was recovered from the yeast, and sequenced with S6 (5’dCTGGGACAGCCAAGTCTGT3’), R6 (5’-dCCTCATTCAGCTCTCGGAA3’) primers to
reveal the mutations. 53 yeast colonies were examined, in which 63 mutations were sequenced, 29
were G to T transversions, and 16 occurred at hot spots of lung cancer such as codon 157 (GTC
→ ATC), 244 (GGC→GAC), 245 (GGC→TGC), 249 (AGG→ATG, AGG→AGC), and 273
(CGT→CTT).
Co-generation of nitric oxide and superoxide induced mutation at codon 248 in the p53 gene.57
Human bronchial epithelial cells (BEAS-2B) were treated with nitric oxide donor systems and
harvested 72 h later. The genomic DNA was extracted, purified and subjected to fish-RFLP/PCR
to detect mutations. Mutations in codon 248 were observed as CGG→TGG, CGG→CAG, and
CGG→CCG.
Codon specific mutations in the p53 exon 7 were investigated by ultraviolet B light radiation
in human skin fibroblasts.58 Fibroblasts were treated with UVB radiation grown for 72 h. Then,
DNA was extracted and mutations in p53 codons 247-250 were found by the genotypic RFLPPCR assay. Mutations occurred in codon 250 (CCC→ACC), codon 249 (AGG→AGT), codon 248
7

(CGG→AGG), and codon 247 (AAC→AAA, AAC→AAT). These base pair changes are most
likely due to pyrimidine photodimers as premutagenic lesions.
1.4 Protein Modifications
1.4.1 By Metabolites
Protein adducts by carcinogens are considered as surrogates for DNA adducts. The reactive
metabolites react with proteins by covalently binding nucleophilic amino acid residues. 59 The
target proteins are usually hemoglobin from red blood cells and albumin from blood plasma.60
BPDE adducted hemoglobin (Hb) and serum albumin (SA) has been investigated61 and 4-ABPHb adducts have been used as a biomarker distinguishing between smokers and nonsmokers. 62
Also, protein adducts formation might disrupt protein structure or function causing damage to
submembrane organelles, metabolic pathways, or cytological processes, which play a causal role
in initiating pathophysiological process of chemical-induced nerve cell injury.63
Drug induced toxicity is another type of protein damage due to drugs. Many drugs are
oxidative bioactivated to reactive metabolites by enzymes and covalently bind on proteins. The
mechanisms of toxicity by protein adducts are considered as either changing target protein
functions or stimulating an immunological response of the host immune system against modified
proteins.64 The target tissues of protein adducts depend on the location of bioactivation enzymes,
drug accumulation, and chemical stability of reactive metabolites. Liver is usually the major
affected organ since most drugs are metabolized in the liver.65
1.4.2 Post-Translational Modification
Post-translational modification (PTM) of protein is the process of adding chemical groups to
its amino acid residues during protein synthesis. It’s important for protein functionalization and
8

cell signaling.66 There are over 200 protein modifications detected with current technologies.67
Phosphorylation is one of the most common PTM, which is essential for intracellular signaling.68
Glycosylation is another type of PTM, in which carbohydrate molecules are attached to the
proteins. Glycosylation can promote protein folding and improve the stability of proteins. 69
Different glycan structures on therapeutic antibodies would have different clearance rate, which
may impact the efficiency of antibody drugs.70 There are also types of PTM caused by oxidative
stress. Carbonylation of protein is one type of PTM because of oxidation, is usually considered as
a major biomarker of oxidative stress-related diseases.71 Cysteine oxidation is another type of PTM
by oxidation by producing sulfenic acid (R-SOH), sulfinic acid (R-SO2H), and sulfonic acid (RSO3H), which play important roles in cell signaling and protein functions.72
1.5 Mass Spectrometry in DNA Oxidation
Mass spectrometry (MS) has emerged as a powerful modern tool to investigate structurally
damaged DNA.5 Stable isotope labeling of DNA has been widely used along with MS to examine
the reactive sites and cytosine methylation on the formation of 8-oxoG and downstream oxidation
products of reactions with nitrosoperoxycarbonate and riboflavin-mediated photolysis using
multiple reaction monitoring (MRM).41 Experiments were done on

15

N3,13C1-labeled DNA

oligodeoxynucleotides synthesized by standard phophoramidite chemistry using a DNA
synthesizer.

15

N3,13C1-dG phosphoramidite and

15

N3,13C1-dG phosphoramidite were also

synthesized and used. Percent oxidation at labeled guanine equals the LC MRM peak area of the
labeled oxidation product divided by the sum of LC MRM peak areas of labeled and unlabeled
oxidation products. In this way, the amounts and locations of 8-oxoG and other products formed
on the DNA strands are revealed.
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LC-MS/MS approaches have been developed to size and sequence DNA oligonucleotides up
to 20 bp.73,74 QTOF-MS/MS was employed to detect sequence and agent specificity on the further
oxidation products of 8-oxodG in DNA oligonucleotides.42,75 Synthesized 8-oxodG containing
oligonucleotides were oxidized by two oxidants (nitrosoperoxycarbonate and riboflavin-mediated
photooxidation) to detect the 8-oxodG derived oxidation products. DGh containing
oligonucleotides were found as the predominant products. The relative amounts of 8-oxodG
products by nitrosoperoxycarbonate oxidation is not affected by sequences; while products of
riboflavin-mediated photooxidation of 8-oxodG are sequence dependent.
1.6 Mass Spectrometry in Protein Modification
Mass spectrometry is a powerful tool to detect the protein modifications. The protein
modification events are detected by increases in masses of the modifications. Sites of
modifications can be identified from mass shifts in fragment ions generated from fragmentation
(MS/MS) in mass spectrometry.76 The type and sites of modifications are determined by analyzing
the fragmentation spectra of modified peptides. Usually, a database searching on non-modified
peptides is performed to identify proteins, then a database searching of modified peptides within
those proteins is performed.77
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Chapter 2 Direct LC-MS/MS Detection of Guanine Oxidations in Exon 7 of the p53 Tumor
Suppressor Gene
2.1 Abstract
Oxidation of DNA by reactive oxygen species (ROS) yields 8-oxo-7,8-dihydroguanosine (8oxodG) as primary oxidation product, which can lead to downstream G to T transversion mutations.
DNA mutations are nonrandom and mutations at specific codons are associated with specific
cancers, as widely documented for the p53 tumor suppressor gene. Here, we present the first direct
LC-MS/MS study (without isotopic labeling or hydrolysis) of primary oxidation sites of p53 exon
7. We oxidized a 32 base pair (bp) double-stranded (ds) oligonucleotide representing exon 7 of the
p53 gene. Oxidized oligonucleotides were cut by a restriction endonuclease to provide small
strands and enable positions and amounts of 8-oxodG to be determined directly by LC-MS/MS.
Oxidation sites on the oligonucleotide generated by two oxidants, catechol/Cu2+/NADPH and
Fenton’s reagent, were located and compared. Guanines in codons 243, 244, 245 and 248 were
most frequently oxidized by catechol/Cu2+/NADPH with relative oxidation of 5.6 % 7.2 %, 2.6 %,
and 10.7 %, respectively. Fenton’s reagent oxidations were more specific for guanines in codons
243 (20.3 %) and 248 (10.4 %). Modeling of docking of oxidation agents on the ds-oligonucleotide
were consistent with the experimental codon oxidation sites. Significantly, codons 244, 248 are
mutational “hotspots” in non-small cell and small cell lung cancers, supporting a possible role of
oxidation in p53 mutations leading to lung cancer.
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2.2 Introduction
Reactive oxygen species (ROS) such as hydroxyl radical (•OH), singlet oxygen (1O2),
peroxynitrite (ONOO-) and superoxide (O2•-) play important roles in living organisms, e.g. as
messengers in cell signaling cascades. However, they can also induce cell apoptosis during
oxidative stress, 1 featuring unregulated accumulation of ROS from endogenous or exogenous
processes. Oxidative stress likely plays roles in aging, cardiovascular disease, Parkinson’s disease,
and cancer.2-6
One source of ROS is oxidation of transition metals by H2O2, to produce •OH, which is
usually called Fenton’s reaction, especially when involving ferrous ions.7-9 Another source of ROS
is redox cycling of quinones and other metabolites involving Cu2+ and NADPH. 10 - 14 When
chemicals or their metabolites lead to DNA damage, they are referred to as genotoxic. Catechol, a
model for quinoid metabolites, undergoes redox cycling in the presence of Cu2+ and NADPH that
leads to a 2-electron oxidation to o-quinone, which subsequently undergoes two 1-electron
enzymatic reductions back to catechol by NADPH. ROS including H2O2, O2•-, and •OH are formed
in these redox cycles (Scheme 2.1), and can oxidize DNA in vitro.15,16 Also, polycyclic aromatic
hydrocarbon (PAH) o-quinones are implicated as causes of mutations in tumor suppressor genes,
and are known risk factors for lung cancer.17
Guanine is the main oxidation target in genes due to having the lowest redox potential of the
DNA nucleobases (1.3 V vs. NHE).18,19 The primary oxidation product of deoxyguanosine is 8oxo-7,8-dihydrodeoxyguanosine (8-oxodG), which can lead to G to T transversion mutations
during DNA replication.20,21 Cancer may result when such mutations occur at tumor suppressor
genes or oncogenes.22,23
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Scheme 2. 1 Proposed redox cycling pathway for DNA oxidation induced by catechol, NADPH
and Cu2+.
Tumor suppressor genes provide cancer protection by coding for proteins that inhibit cell
proliferation and tumor development.24 TP53 (or p53) was identified as a tumor suppressor gene
in the 1980s.25 It encodes p53 protein that regulates cell cycle and inhibits tumor growth. Mutations
in p53 genes are found in > 50% of all human cancers. 26 - 28 Extensive databases document
mutations found at specific p53 codons from human tumors and cancer cell lines, and show that
many mutations are well-correlated with specific cancers. Most p53 mutations occur at exons 58.29 E.g. highly mutated codons 157, 158, 248, 249 appear in lung cancers, mutated codons 175,
248, 273 are found in breast cancer, and mutated codons 175, 248, 282 occur in liver cancer.30,31
Thus, DNA oxidation at specific sites that lead to mutations at the same sites may be possible to
correlate with specific cancers.
Early work in p53 gene oxidation employed gel electrophoresis of DNA fragments. The
structure of guanine oxidation products was not addressed, and most studies focused on the
resulting mutations. Both guanine residues (AGG→ATG, AGG→AGT) in codon 249 mutated to
thymine as a result of Fenton oxidation in human fibroblasts.32 Oxidation of human skin fibroblasts
by UVB light (280-320 nm) caused G to T mutations at the third position of codon 249
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(AGG→AGT).33 PAH-induced oxidation of p53 has been observed at hot spots associated with
lung cancer, including codons 245 (GGC→TGC), 249 (AGG→ATG), 273 (CGT→CTT).17
Mass spectrometry (MS) is a powerful tool to detect structurally damaged DNA. 34 LCMS/MS approaches have been developed to size and sequence DNA oligonucleotides up to 20
bp. 35 ,36 QTOF-MS/MS was employed to detect sequence and agent specificity on the further
oxidation products of 8-oxodG in DNA oligonucleotides.37,38 In that study, synthesized 8-oxo-dG
containing oligonucleotides were oxidized to detect the 8-oxodG derived oxidation products, and
standard oligonucleotides were not used. Stable isotope labelling of DNA has been widely used
with mass spectrometry to examine the reactive sites and cytosine methylation on the formation of
8-oxodG and downstream oxidation products of reactions with nitrosoperoxycarbonate and
riboflavin-mediated photolysis. 39 This approach detected the amount of 8-oxodG and other
products formed, but isotopic labelling syntheses and enzymatic oligonucleotide digestion are
required.
To investigate reactive sites, the positional isomeric modified oligonucleotides must be
separated. Harsch et al. reported separation of isomeric benzo[c]phenanthrene diol epoxide
adducted HRPT gene sequence by using ammonium acetate as ion-pairing reagent.40 Xiong et al.
identified nine isomeric (±)-anti-7r,8t-dihydroxy-9t,10-epoxy-7,8,9,10-tetrahydro-benzo[a]pyrene
adducted oligonucleotides using ion pair reagent triethylammonium bicarbonate (TEAB). 41
Sharma et al. used TEAB to separate oligonucleotides adducted by N-acetylaminofluorene, Nhydroxy-4-aminobiphenyl and (±)-anti-benzo[a]pyrene diol epoxide to investigate the site
selectivity.42,43 All these are adduction modification, but there is merely report on investigating
DNA oxidation sites.
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We previously described a restriction enzyme-assisted LC-QTOF MS/MS oligonucleotide
sequencing methodology to detect covalent adduction on ds-oligonucleotides longer than 20 base
pair (bp).44 We used this approach to evaluate reaction products of oligonucleotides with the diol
epoxide metabolite of benzopyrene (B[a]P) and examined the effect of cytosine methylation on
adduct reaction kinetics of exon 7 of the p53 gene.45 In the present paper, we tailor this approach
to directly detect 8-oxodG formation in oxidized ds-DNA strands. We apply the method to the 32
bp exon 7 ds-oligonucleotide fragment of the p53 gene, representing p53 codons 242 to 253
(Scheme 2.2). Ion pairing reagent TEAB was used to separate positional isomeric oxidative
oligonucleotides. The primary products of exon 7 oligonucleotide from catechol/Cu2+/NADPH and
Fenton’s reagent oxidation were compared. Analysis of >20 bp oligonucleotides is facilitated by a
restriction enzyme that cuts the oligonucleotide into smaller fragments suitable for MS/MS
sequencing. Using this approach, Fenton’s reagent oxidized G at codons 243 and 248; the catechol
system oxidized guanines at codons 243, 244, 245, and 248, correlating with lung cancer mutation
hot spots at codons 245, 248. The reacting guanines in codons 245 and 248 are C-phosphateGuanine (CpG) sites, and the guanine in codon 248 is also the most reactive towards SN2 reactions
with B[a]P diol epoxide.45 The p53 oxidation sites have been uncovered in a purely chemical
reaction, and this is of course much less complex than in vivo in humans. However, we find that
the most chemically reactive p53 codons present correlations to mutation sites found in tumors.

Scheme 2. 2 Exon 7 of p53 gene showing reactive codons in color. Arrows show cut points for
restriction enzyme Nla III, and resulting fragments obtained.
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2.3 Experimental Section
2.3.1 Chemicals and Materials
Custom oligonucleotides were from MilliporeSigma. Catechol, D-glucose 6-phosphate
sodium salt (G6P), β-nicotinamide adenine dinucleotide phosphate sodium salt hydrate (NADP+),
glucose-6-phosphate dehydrogenase (G6PDH), CuCl2, MgCl2, FeSO4.7H2O, H2O2 solution (30 %
w/w), triethylammnium bicarbonate (TEAB, 1.0 M, pH 8.4-8.6), 3-nitrobenzyl alcohol,
chloroform-isoamyl alcohol mixture (24:1), phenol-chloroform-isoamyl alcohol mixture (25:24:1)
were from MilliporeSigma. Restriction enzyme, Nla III was from New England Biolabs Inc.
2.3.2 Oligonucleotide Oxidation and Restriction Enzyme Cutting
100 μg of oligonucleotides in 50 mM pH 7.2 Tris buffer with 50 mM NaCl were incubated
in a total volume of 200 μL with 1 mM catechol, 50 μM CuCl2, and NADPH regeneration system
(10 mM G6P, one unit G6PDH enzyme, 0.8 mM NADP+, 1 mM MgCl2) at 37 ℃ for 12 hours.
Alternatively, 100 μg of oligonucleotides in 10 mM pH 5.5 acetate buffer with 50 mM NaCl in a
total volume of 200 μL were incubated with Fenton’s reagent containing 0.1 mM FeSO4 and 40
mM H2O2 at 37 ℃ for 4 hours with constant stirring. Amicon Ultra-0.5 3K centrifugal filters from
MilliporeSigma were used to remove excess catechol, NADPH system, and FeSO4 products. The
reaction mixture was put into the filter vial and centrifuged at 13,000 rpm for 30 min. Dsoligonucleotide fragments were retained on the filter, which was then reversed, put into a new vial
and centrifuged at 13,000 rpm for 30 min to collect the approximately 50 μL of ds-oligonucleotide.
Then, 15 μL (150 units) of restriction enzyme Nla III, 20 μL of 10 × NE buffer (New England
Biolabs, 1× buffer contains 50 mM potassium acetate, 20 mM tris-acetate, 10 mM magnesium
acetate, 100 ug/ml BSA, pH 7.9) and 115 μL of pure water were added to the reacted
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oligonucleotide solution, and this solution was incubated 37 ℃ for 12 hours to cut oligonucleotides
into smaller fragments.
2.3.3 Removal of Enzymes and Salts
200 μL of phenol/chloroform/isoamyl alcohol (25:24:1) was added to the mixture from the
above process. The mixture was shaken for 15 min, then centrifuged at room temperature for 10
min. Then, the upper aqueous solution was carefully transferred to a fresh tube for subsequent
extraction. The solution was extracted with phenol/chloroform/isoamyl alcohol (25:24:1) three
times, and chloroform/isoamyl alcohol (24:1) twice. The resulting aqueous oligonucleotide
solution was about 200 μL.
100 μL of 7.5 M ammonium acetate was added to the DNA solution for ethanol precipitation,
then 700 μL of cold ethanol was added to the mixture. The solution was mixed well, and stored at
-20 ℃ for 1 hour, followed by centrifugation at 4 ℃ for 30 min. The supernatant was carefully
removed, then 1 mL of 70% cold ethanol in water was used to wash the pellet, which was then
dried under N2 and dissolved in 100 μL of HPLC-grade water. This solution was heated at 90 ℃
for 15 min and cooled rapidly to convert ds- to ss-oligonucleotides, then stored at -20 ℃.
2.3.4 UPLC-QTOF MS/MS Analysis
A Dionex Ultimate 3000 UPLC with a Gemini C-18 column (150 × 0.5 mm, 3 μm particle
size) was used with mobile phases 25 mM triethylammonium bicarbonate (TEAB, solvent A) and
methanol (solvent B).44 A gradient of 15% B for 2 min followed by increasing from 15 % B to
20% B over 36 min, then back to 15% B for another 2 min at flow rate 8 μL/min was used. The
UHPLC was interfaced to an AB Sciex QSTAR Elite mass spectrometer in negative ion mode with
a -4500 V ion spray voltage, -60 V declustering potential at 300 ℃. 0.1% of m-nitrobenzyl alcohol
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was infused 4 μL/min to mix with the LC flow post-column using a three way connector before
entering the QSTAR to enhance oligonucleotide charging and signal intensity. 46 The ssoligonucleotides were analyzed by time of flight scan mode for sizing unoxidized and oxidized
fragments. Product ion scan mode was used for sequencing oxidized fragments at -40 eV collision
energy. In most cases, analysis was restricted to singly oxidized oligonucleotides.
2.3.5 Molecular Modelling
The standard B-DNA form of 32 bp p53 exon 7 ds-oligonucleotide was modelled using
online DNA sequence to structure tool 47 and solvated using CHIMERA software 48. An Amber
solvation model was used with appropriate box size to accommodate water molecules.45 Autodock
4.2.6 was used for docking.49 Ligands (Fe2+, Fe3+, H2O2, •OH, catechol, benzoquinone, Cu(I)OOH)
were imported into the model software. A Lamarckian genetic algorithm (LGA) was used in
Autodock 4.2.6 to find the binding energy between the oligonucleotides and the ligands.
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2.4 Results
2.4.1 Method Development
The 32 bp exon 7 p53 fragment was oxidized with catechol or Fenton’s reagent, then the
oxidized ds-oligonucleotide were cut to smaller size suitable for LC-MS/MS. Restriction enzyme
Nla III cuts ds-DNA after the sequence CATG (no cleavage after CATG in Fragment 1, due to no
bases after G in the complimentary strand), resulting in two ds fragments of 13 and 19 bases, but
leaving unpaired CATG at the ends (Scheme 2.2). After cutting, heat treatment is used to convert
all ds-oligonucleotides to single strands.
Our focus was to identify the primary oxidation sites on exon 7, so we developed conditions
to determine 8-oxodG sites in singly oxidized fragments. Our reaction conditions yielded 8-oxodG
as the only oxidation product. If a single dG is oxidized to 8-oxodG, the mass of the reacted ssoligonucleotide increases by 15.999. The identity of each 8-oxodG-containing oligonucleotide was
determined by comparing the measured m/z of the oxidized oligonucleotide to the expected m/z
of the corresponding unreacted species calculated using Mongo Oligo Mass Calculator, v2.08.50
M/z values for the four unoxidized and oxidized oligonucleotide fragments are shown in Table 2.1.
For example, m/z 1002.4 was observed for unoxidized Fragment 1 (Scheme 2.2) with z = -4, and
the 8-oxodG-containing Fragment 1 had m/z = 1006.4 (z =-4). TOF MS spectra of the four
oxidized fragments are in Figure 2.1.
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Table 2. 1 Mass-to-charge ratios of four oligonucleotide fragments containing 8-oxodG

Mol wta
Name

Sequence
(unoxidized)

Fragment 1

Fragment 2
Fragment 3
Fragment 4
a

CATGGGCGGCA
TG
AACCGGAGGCC
CATCCTCA
CCGCCCATG
TGAGGATGGGC
CTCCGGTTCATG

b

Mol wt

Measured

(8-oxodG

m/z

containing)

(unoxidized)

Measuredb
m/z
(8-oxodG
containing)

4012.693

4028.692

1002.4 (-4)

1006.4(-4)

5818.956

5834.955

969.0(-6)

971.7(-6)

2737.439

2753.438

911.8(-3)

917.1(-3)

7107.182

7123.181

1183.7(-6)

1186.4(-6)

Molecular weight based on Mongo Oligo Mass Calculator, v2.08. bBased on the ion with different

charge states in negative ion mode.

Scheme 2. 3 Collision induced dissociation (MS/MS) of DNA fragments resulting in the
generation of wn and an-bn ions.
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Collision-induced dissociation (CID) provided information on the sequence of oxidized
oligonucleotide products by fragmentation of the phosphodiester backbone (Scheme 2.3), forming
an-bn and wn ions.51,52 The position of 8-oxodG was determined by detecting the difference in m/z
values of the an-bn and wn ions of corresponding unoxidized and oxidized oligonucleotides.

Figure 2. 1 Negative-ion ESI-MS of singly oxidized fragments (A) oxidized Fragment 1, m/z
1006.4 (-4), (B) oxidized Fragment 2, m/z 971.7 (-6), (C) oxidized Fragment 3, m/z 917.1 (-3),
(D) oxidized Fragment 4, m/z 1186.4 (-6).

2.4.2 Oxidation by Catechol/Cu2+/NADPH
Catechol is an industrial chemical and a major component of tobacco smoke, 53 and is
classified as a group 2B carcinogen. 54, 55 In the presence of Cu2+ and an enzymatic NADPH
regenerating system, redox cycling of catechol, semiquinone radical, and benzoquinone produces
ROS, which oxidize dG to 8-oxodG in DNA (Scheme 2.1).15,16,56
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Figure 2. 2 LC-QTOF mass spectrometry of Fragment 1 (Scheme 2.2) from Exon 7 oxidized
by Catechol/Cu2+/NADPH. (A) Extracted ion chromatogram for m/z 1006.4 representing z=-4
of singly oxidized products. (B) CID analysis of m/z 1006.4 for peak 1 eluting at 13.6 min and
(C) CID analysis of peak 2 eluting at 14.9 min.
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Figure 2.2A shows an extracted ion chromatogram (XIC) of a selected ion of oxidized exon
7 Fragment 1 (Scheme 2.2) with m/z 1006.4 representing 8-oxodG-containing Fragment 1 with
z=-4. (Most intense charge state ion was used to present XIC.) There are four major peaks in the
chromatogram suggesting that four positional isomers for singly oxidized Fragment 1 were formed
with retention times 13.6 min, 14.9 min, 16.2 min, and 17.9 min. The CID spectrum of fragment
ion 1006.4 for peak 1 is shown in Fig. 2.2B and for peak 2 in Fig. 2.2C.
Figure 2.2A shows an extracted ion chromatogram (XIC) of a selected ion of oxidized exon
7 Fragment 1 (Scheme 2.2) with m/z 1006.4 representing 8-oxodG-containing Fragment 1 with
z=-4. (Most intense charge state ion was used to present XIC.) There are four major peaks in the
chromatogram suggesting that four positional isomers for singly oxidized Fragment 1 were formed
with retention times 13.6 min, 14.9 min, 16.2 min, and 17.9 min. The CID spectrum of fragment
ion 1006.4 for peak 1 is shown in Fig. 2.2B and for peak 2 in Fig. 2.2C.
Differences in a-b and w ions between unoxidized and oxidized Fragment 1 were used to
locate the oxidation sites (i.e. 8-oxodG), as used previously for metabolite adduction sites.35,36,44,57
MS/MS spectrum for Peak 1 of singly oxidized Fragment 1 (Fig. 2.2B) shows increase in mass of
ions from a6-b6 to a8-b8 compared to unoxidized Fragment 1. This indicates that the fifth guanine
was oxidized to 8-oxodG, CATGGoxGCGGCATG. The MS/MS spectrum for peak 2 of singly
oxidized Fragment 1 (Fig. 2.2C) shows an increase in mass of all ions from a9-b9 compared with
that of the unoxidized Fragment 1. This shows that the eighth guanine was oxidized to 8-oxodG,
CATGGGCGoxGCATG, and is confirmed by increases in mass of w ions from w6 ion. Similar
analysis of the third and the fourth peaks, revealed that peak 3 indicates oxidation of the sixth
guanine (CATGGGoxCGGCATG) and peak 4 represents oxidation of the fourth guanine in
CATGoxGGCGGCATG) (Fig. 2.3).
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Singly oxidized Fragment 2 gave m/z of 971.7 at z= -6 (Fig. 2.1B). The XIC of m/z 971.7
(Fig. 2.4A) showed only one major peak, which indicated that only one base on Fragment 2 was
oxidized during the reaction. MS/MS spectra for singly oxidized Fragment 2, m/z 971.7, (Fig. 2.4B)
shows increase in mass of all ions from a6-b6, a7-b7, suggesting that the fifth guanine was oxidized,
AACCGoxGAGGCCCATCCTCA. This is confirmed by increase in mass of w15 and w16 for w
ions. All ions below w14 gave the same m/z values as the unoxidized fragment.
Two unknown peaks were found in oxidized Fragments 1 (20.3 min) and 2 (28.7 min) after
catechol/Cu2+/NADPH oxidation (Fig. 2.2A, 2.4A). They are also positional isomers of oxidized
Fragments 1 and 2, but were not intense enough for reliable identification.
Similar analyses were done on oxidized complimentary strands of Fragments 3 and 4.
Results identified oxidized Fragment 3 with m/z 917.1, z = -3 (Fig. 2.1C) and oxidized Fragment
4 with m/z 1186.4 (Fig. 2.1D), z = -6 (Table 2.1). MS/MS spectra are shown in Fig. 2.5, 2.6. In
Fragment 3, the third and the last guanines were oxidized (CCGoxCCCATG, CCGCCCATGox),
and the fourth guanine in Fragment 4 was oxidized (TGAGoxGATGGGCCTCCGGTTCAG).
Oxidation sites for all the fragments are summarized in Table 2.2.
We estimated the relative abundance of specific oxidized fragments by comparing areas
under extracted ion chromatograms of oxidized fragments to those of unoxidized fragments (Fig.
2.7), assuming that oxidized and unoxidized fragments have similar MS ionization efficiencies.44
Take oxidized Fragment 1 by Catechol/Cu2+/NADPH as an example, Figure 2.2A is the XIC of
oxidized Fragment 1 1006.4 (-4), Figure 2.7A is the XIC of unoxidized Fragment 1 1002.4 (-4). %
oxidized of Peak 1 (CATGGoxGCGGCATG) representing guanine in codon 244 was calculated
by dividing the peak area under peak 1 in Figure 2.2A by the peak area under the peak (unoxidized
Fragment 1) in Figure 2.7A. % oxidized of Peak 2, 3, 4 of oxidized Fragment 1 and oxidized
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Fragment 2 were also calculated using the method described above. The relative amounts of
oxidation in the 32 bp fragment were estimated (Table 2.2). Ratios of relative amounts of oxidation
for codons 248/243 was 1.9, codon 248/244 was 1.3, 248/245 was 4.1.

Figure 2. 3 (A) CID analysis of oxidized Fragment 1 by Catechol/Cu2+/NADPH, m/z 1006.4
for peak 3 eluting at 16.2 min and (B) CID analysis of peak 4 eluting at 17.9 min.
Representative CID fragmentation of a 8-oxodG containing oligonucleotide confirmed the
identification and location of the 8-oxodG.
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Figure 2. 4 LC-QTOF mass spectrometric analysis of 8-oxodG containing Fragment 2
oxidized by catechol/Cu2+/NADPH. (A) Extracted ion chromatogram for fragment m/z
971.7, z = -6 of singly oxidized Fragment 2. (B) CID analysis of oxidized Fragment 2,
m/z 971.7 for peak eluting at 24.5 min.
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Figure 2. 5 (A) Extracted ion chromatogram for fragment m/z 917.1 representing -3 charge of
singly oxidized Fragment 3 by Catechol/Cu2+/NADPH. (B) CID analysis of oxidized Fragment
3, m/z 917.1 for peak 1 eluting at 8.8 min and (C) CID analysis of peak 2 eluting at 10.0 min.
Representative CID fragmentation of an 8-oxodG containing oligonucleotide confirmed the
identification and location of the 8-oxodG.
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Figure 2. 6 (A) Extracted ion chromatogram for fragment m/z 1186.4 representing -6 charge
of singly oxidized Fragment 4 by Catechol/Cu2+/NADPH. (B) CID analysis of oxidized
Fragment 4, m/z 1186.4 for the peak eluting at 33.1 min. Representative CID fragmentation
of an 8-oxodG containing oligonucleotide confirmed the identity and location of the 8-oxodG.
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Figure 2. 7 Extracted ion chromatogram for (A) fragment m/z 1002.4 representing -4 charge of
unoxidized Fragment 1; (B) fragment m/z 969.0 representing -6 charge of unoxidized Fragment
2; (C) fragment m/z 911.8 representing -3 charge of unoxidized Fragment 3; (D) fragment m/z
1183.7 representing -6 charge of unoxidized Fragment 4 after Catechol/Cu2+/NADPH treatment.
2.4.3 Oxidation by Fenton’s Reagent
Deoxyguanosine in DNA is easily oxidized to 8-oxodG by Fenton’s reagent. The active
oxidant in Fenton’s reagent is thought to be •OH,58,59 and oxidation products of 8-oxodG have also
been identified.9,60,61 We found none of these overoxidation products under our conditions.
Oxidation products of p53 exon 7 by Fenton’s reagent revealed several differences from
oxidation by catechol/Cu2+/NADPH. Fig. 2.8A shows there is only one major peak in the extracted
ion chromatogram (XIC) of singly oxidized Fragment 1, indicating only one base was oxidized.
The MS/MS spectrum for singly oxidized Fragment 1 (Fig. 2.8B) shows an increase in mass of all
ions from a5-b5 to a7-b7 compared to the unoxidized fragment. This indicates that the fourth guanine
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was oxidized to 8-oxodG, CATGoxGGCGGCATG, confirmed by increased mass of w ions above
w10. All ions from w2 to w9 had the same m/z as that of the unoxidized fragment.

Figure 2. 8 LC-QTOF mass spectrometric analysis of 8-oxodG containing Fragment 1
oxidized by Fenton’s reagent. (A) Extracted ion chromatogram (XIC) for fragment m/z
1006.4 representing -4 charge of singly oxidized Fragment 1. (B) CID analysis of oxidized
Fragment 1, m/z 1006.4 for peak eluting at 17.9 min.
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Oxidized Fragment 2, and Fragment 4 gave similar results as catechol/Cu2+/NADPH
oxidation (Fig. 2.9A, 2.9C). For Fragment 3 (Fig. 2.9B), there is only one major peak for the
oxidized Fragment 3. Results are summarized in Table 2.2. The relative amounts of oxidation by
Fenton’s reagent were also estimated (Table 2.2) by comparing areas under extracted ion
chromatograms. Ratio of relative amounts of oxidation for codons 248/243 was 0.5.

Figure 2. 9 Extracted ion chromatogram for (A) fragment m/z 971.7 representing -6 charge
of singly oxidized Fragment 2; (B) fragment m/z 917.1 representing -3 charge of singly
oxidized Fragment 3; (C) fragment m/z 1186.4 representing -6 charge of singly oxidized
Fragment 4 by Fenton’s reagent.
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Table 2. 2 Catechol/Cu2+/NADPH and Fenton’s reagent oxidation results on fragments of p53
exon 7 compared to mutation sites from the p53 database.
LC-MS/MS Data
Oxidants

Fragments

Sequence

Codon
(%)

Mutation
hot spots

Fragment 1 CATGGGCGG CATG Gox GCGGCATG
CATG

244
(3.2)

244a

CATGGGC Gox GCATG

245
(2.6)

245b,d

CATGG Gox CGGCATG

244
(5.0)

244a

CAT Gox GCGGCATG

243
(5.6)

243c

AACC Gox
GAGGCCCATCCTCA

248
(10.7)

248a,b,c,d,e

Catechol/
Cu2+/
NADPH
Fragment 2

AACCGGAG
GCCCATCCT
CA
Complementary strands
Fragment 3 CCGCCCATG
Fragment 4 TGAGGATGG
GCCTCCGGT
TCATG
Fenton’s
Reagent

CC Gox CCCATG
CCGCCCAT Gox
TGA Gox
GATGGGCCTCCGGTTCAG

Fragment 1 CATGGGCGG CAT Gox GGCGGCATG
CATG

243
(20.3)

243c

Fragment 2

248
(10.4)

248a,b,c,d,e

AACCGGAG
GCCCATCCT
CA
Complementary strands
Fragment 3 CCGCCCATG
Fragment 4 TGAGGATGG
GCCTCCGGT
TCATG

a

Gox = Oxidized G

Small cell lung cancer.

b

AACC Gox
GAGGCCCATCCTCA

CC Gox CCCATG
TGA Gox
GATGGGCCTCCGGTTCAG

Non-small cell lung cancer.

Colorectal cancer. e skin cancer.
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c

Hepatocellular carcinoma (HCC).

d

2.4.4 Modelling of Oxidant Binding
In DNA oxidation mediated by catechol, NADPH and Cu2+, molecular oxygen is reduced to
O2•- and H2O2, and catechol reacts with Cu2+ yielding Cu+ and benzoquinone (Scheme 2.1). Also,
Cu+ reacts with H2O2 to form •OH radical and Cu(I)-hydroperoxyl complex (Cu(I)OOH), which
may lead DNA strand breaks. In Fenton’s reagent oxidation, Fe2+ reacts with H2O2 to form Fe3+
ions and •OH radical. To gain insight into the codon specificity of the oxidations, molecular
modelling was done with AutoDock 4.2.6, by docking each possible involved species (Fe2+, Fe3+,
H2O2, •OH, catechol, benzoquinone, and Cu(I)OOH) with the B-DNA form of the exon 7 dsoligonucleotide. Parameters were set with 25,000,000 evaluations and 50 docked conformations
for an individual docking computation. Examples of preferred Fe2+ binding site on exon 7 from
this analysis is shown in Figure 2.10, and preferred catechol sites in Figure 2.11. The preferred
binding positions and binding free energies (ΔGb) were estimated from this analysis. ΔGb values
were used to calculate relative apparent binding constants from lnKb=-ΔGb/RT, where R is the
ideal gas constant and T is temperature in Kelvins. (Table 2.3) For Fe2+, 35 out of 50 docked
conformations were between the fourth and fifth guanines in Fragment 1 (Fig. 2.10), but the
binding is quite weak. For catechol, preferred binding was found at multiple positions, including

Figure 2. 10 Model of Fe2+ docked at preferred site (arrow) near reactive guanine in the
B form of the 32 bp exon 7 p53 fragment.
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the fourth, fifth, sixth and eighth, and thirteenth guanines (Fig. 2.11) and the binding is stronger.
Results for all possible ROS are listed in Table 2.3.
The two unknown peaks in oxidized Fragment 1 (20.3 min) and Fragment 2 (28.7 min) from
catechol-mediate oxidation (Fig. 2.2A, 2.4A) were not intense enough for reliable identification.
However, docking results (Fig. 2.11D) are consistent with the possibility that the thirteenth
guanine was oxidized in Fragment 1. and G in codon 249 was probably oxidized in Fragment 2
due to codon 249 is also a “hotspot” in many cancers, such as liver, lung, and hepatocellular
carcinoma.30

Figure 2. 11 Models of catechol in yellow docking near reactive guanines in the B form of the
32 bp exon 7 p53 fragment showing catechol docked (arrows) (A) with the fourth and fifth
guanines; (B) with the sixth guanine; (C) with the eighth guanine; (D) with the thirteenth
guanine.
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Table 2. 3 Computed binding positions, numbers of docked confirmations, binding free energies,
and binding constants of possible ROS on the 32 bp fragment of exon 7 p53 gene.
Species

Binding Position

Codon

Numbers of

Binding

Binding

Docked

Energy,

Constant,

Conformations

kcal.mol-1,

Kb, M-1

ΔG
4-5

243

35

0.04

0.94

6-7

244

15

0.04

0.94

15

247

27

-4.02

6.9×102

13

246

8

-3.64

3.7×102

4

243

2

-3.31

2.2×102

16

248

1

-3.36

2.4×102

9-10

245

8

-3.53

3.1×102

10

245

1

-3.62

3.6×102

7-8

245

2

-3.72

4.2×102

6-7

244

1

-3.27

2.0×102

4-5

243

21

0.04

0.937

5-6

244

3

0.04

0.937

6-7

244

26

0.04

0.937

17

248

22

-1.9

2.18×10

Phosphate between 8-

245

28

-1.9

2.18×10

17-18

248

44

-3.24

1.92×102

6

244

5

-3.06

1.44×102

Iron (II)

Catechol

Iron (III)

.OH

9
Superoxide
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12

246

1

-2.84

1.00×102

6

244

3

-3.21

1.83×102

17

248

2

-3.33

Phosphate between 3-

243

1

-3.13

1.61×102

245

27

-3.13

1.61×102

248

3

-3.08

1.48×102

245

9

-3.33

2.24×102

246

5

-3.52

3.05×102

13

246

9

-3.97

6.33×102

7-8

245

10

-4.19

8.98×102

15

247

31

-4.63

1.84×103

7-8

245

1

-2.73

8.39×10

16-17

248

2

-3.01

1.33×102

15

247

10

-2.73

8.39×10

6

244

11

-2.84

1.00×102

8

245

11

-2.72

8.31×10

18

248

11

-2.99

1.28×102

13

246

4

-2.52

5.97×10

2.24×102

4
Phosphate between 8H2O2

9
Phosphate between
17-18
Phosphate between 910
Phosphate between
13-14

Quinone

Cu(I)OOH
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2.5 Discussion
Results above demonstrate successfully development of LC-MS/MS methodology to
directly locate primary oxidation sites in ds-oligonucleotides of >20 bp without labeling or
hydrolysis. This is the first report directly identifying multiple oxidation sites in an intact dsoligonucleotide. The restriction enzyme assisted methodology is simple, reliable, relatively rapid,
and facilitates direct detection and mapping of modified sites. It does not require stable isotope
labelling or DNA hydrolysis.
Results reveal that primary oxidation sites involve only guanines on the p53 exon 7
oligonucleotide. This is consistent with guanines as the most easily oxidized of the DNA
nucleobases. In general, reactivity of specific guanines within the exon 7 p53 ds-fragment are
influenced additionally by neighboring bases and to some extent by secondary structure of the
oligonucleotide.45 The most frequently oxidized guanine by catechol/Cu2+/NADPH in the present
study was in codon 248 (11%, Table 2.2), which correlates with codon 248 as a major mutation
hot spot in many cancers.30 Guanines within codons 243, 244 and 245 were oxidized to a smaller
extent. Thus, there is a quantitative correlation between the high reactive frequency of codon 248
in the p53 exon 7 oligonucleotide with its high mutated frequency in cancers using an oxidation
process that mimics oxidations mediated by redox active metabolites (Scheme 2.1).10-14,17 However,
in Fenton’s reagent oxidation, which may or may not have a directly analogous process in humans,
guanine in codon 248 gave a smaller extent of oxidation (Table 2.2) than codon 243.
According to the p53 database,30 the mutation frequency ratio of codons 248/243 is 24,
248/244 is 7, 248/245 is 2. Our ratios of relative amounts of oxidation by catechol/Cu2+/NADPH
for codons 248/243 was 1.9, and for codons 248/244 was 1.3, which are smaller than the mutation
ratios. While we would not expect exact numerical correspondence in codon reactivity and
43

mutation frequency, the lower reactivity ratios involving guanine in codon 243 may be related to
it being the first guanine in our exon 7 oligonucleotide and more reactive due to its proximity to
the end of a strand.44,62 Also, the guanine in codon 248 (CGG) is a CpG site. In vivo, all cytosines
in CpG sites are methylated, which may increase the reactivity and mutation frequency of the
neighbor guanine in tumors.39,45,63 For 248/245, the oxidation reactivity ratio was 4.1, which is
larger than that for mutations. This could be related to the first guanine in codon 245 (GGC) being
a CpG site, making the guanine more reactive in vivo, resulting in a smaller mutation ratio.
The ratio of relative amounts of oxidation for codons 248/243 was 0.5 from Fenton’s reagent
oxidation, which is much lower than that in the database. Fenton’s reagent is just an oxidant, not a
carcinogen, and may simply oxidize the most accessible guanine with lowest oxidation potential
in the sequence. The guanine in codon 243 (ATG) is close to the end of the fragment, adjacent to
AT sequence, and may be more exposed due to a partially unwound duplex with fewer hydrogen
bonds.44,62 Thus, the guanine in codon 243 may be more reactive in the fragment than the guanine
in codon 248 (CGG) under in vitro condition.
Oxidations of guanines at codon 245 (GGC), 246 (ATG), 248 (CGG), and 249 (AGG) were
observed in isotopic labeled guanines in oligonucleotides.39 Two distinct sites, first guanine in
codon 245 (GGC) and first guanine in codon 248 (CGG) had the highest oxidation percentage at
18.7% and 14.2 %, compared to our values 2.6 % and 10.7 %, respectively. This may because both
guanine sites of highest reactivity had an identical sequence context

Me

CGG with a methylated

cytosine on the 5’ side. In our exon 7, the cytosine is non-methylated, and was less easily oxidized.
Another important observation is the single major peak for oxidized Fragment 1 with
Fenton’s reagent (Fig. 2.8A), as opposed to four major peaks for oxidized Fragment 1 with
catechol/Cu2+/NADPH (Fig. 2.2A), suggesting Fenton’s reagent is more specific towards DNA
44

oxidative damage in our system. Several reports indicated that free hydroxyl radical caused DNA
damage with no marked site specificity. 64,65 But some investigations show iron (II) binding to
phosphate groups and a guanine N-7 moiety first, with subsequent oxidative damage of dG,
oligomers, and calf-thymus DNA in solution.66-68
Docking studies showed that 35 out of 50 conformations of exon 7 oligonucleotide had Fe2+
docked between the fourth and fifth guanines in Fragment 1 (Fig. 2.10, Table 2.3), somewhat
consistent with Fe2+ binding weakly at a specific guanine prior to the actual oxygen transfer leading
to 8-oxodG. However, catechol (Fig. 2.11) was found to bind more strongly at multiple positions,
including the fourth, fifth, sixth, eighth, and thirteenth guanines, which correlates with
experimental results showing multiple products (Fig. 2.2, Table 2.2). Other possible ROS reactants
in the catechol reaction also had multiple preferred binding positions on the exon 7 oligonucleotide
(Table 2.3). Thus, the molecular modelling results are consistent with the broader codon specificity
found in catechol-induced DNA oxidation.
2.6 Conclusion
We describe above a LC-MS/MS methodology to directly sequence and quantify the
oxidation sites on ds-oligonucleotides of >20 bp. The high oxidation frequency at codon 244 and
248 with catechol/Cu2+/NADPH, a model for quinoid drug metabolites, coincides with high
mutation frequency of the p53 gene in lung and other cancers. Fenton’s reagent specificity in
oxidation may be consistent with binding of a key oxidizing component on the oligonucleotide
near the oxidation site before subsequent oxygen transfer to guanines. On the other hand, multiple
binding sites of the model metabolite catechol may explain multiple exon 7 codons oxidized by
catechol/Cu2+/NADPH.
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Chapter 3 Organ-Specific Screening for Protein Damage Using Magnetic Bead Bioreactors
and LC-MS/MS
3.1 Abstract
A new 96-well plate methodology for fast, enzyme-multiplexed screening for metaboliteprotein adducts was developed. Magnetic beads coated with metabolic enzymes were used to make
potentially reactive metabolites that can react with test protein in the wells, followed by sample
workup in multiple 96-well filter plates for LC-MS/MS analysis. Incorporation of human
microsomes from multiple organs and selected supersomes of single cyt P450 enzymes on the
magnetic beads provided a broad spectrum of metabolic enzymes. The reacted protein was then
isolated, denatured, reduced, alkylated, digested, and peptides collected in a sequence of 96-well
filter plates for analysis). Method performance was evaluated by trapping acetaminophen reactive
metabolite N-acetyl-p-benzoquinoneimine (NAPQI) with human glutathione S-transferase pi
(hGSTP) as a model target protein. Relative amounts of acetaminophen metabolite and hGSTP
adducts were compared with ten different cyt P450 enzymes. Human liver microsomes and
CYP1A2 supersomes showed the highest bioactivation rate for adduct formation, in which all four
cysteines of hGSTP reacted with NAPQI. This method has the potential for fast multi-enzyme
protein adduct screening with high efficiency and accuracy.
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3.2 Introduction
Protein damage by drugs or pollutants most often involves bioactivation to a reactive
electrophilic metabolite followed by reaction with a nucleophilic moiety on proteins. 1-3 these
metabolite reactions on proteins can change or destroy protein functions or provoke an antigen
response, resulting in organ toxicity in humans.4,5 Drug-protein adducts are often monitored in the
pharmaceutical industry by using radioisotope-tracers in vitro assays. 6 Other methods include
enzyme-linked immunosorbent assay and Western blots, and liquid chromatography-mass
spectrometry7,8 that have not implemented multiplexed enzyme or magnetic bead approaches.
Liquid chromatography-mass spectrometric (LC-MS) proteomic analysis is a powerful tool
to detect protein modifications.9-11 Typical shotgun proteomics starts with digestion of proteins in
the mixture and separation of resulting peptides by HPLC, then identifies the peptides by tandem
MS. A reliable, highly parallel sample preparation methodology to facilitate multiple-enzyme
protein damage screening would be a valuable tool in molecular toxicity assessment and improve
cost-effectiveness.12-14
96-Well filter plates (96FASP) are commonly used in protein sample preparation methods14,15
to accomplish buffer-exchange, denaturation, reduction, alkylation, and digestion. The weakness
of sample preparation in this format is low centrifugation speed, limited to ~2,000 × g. Therefore,
many washing steps with centrifugation take 4-6 hrs before digestion. Protein precipitation with
acetone under low centrifuge speed in 96-well plates (96PACS) can be used as a faster high
throughput sample preparation approach. 16 Arul et al. developed automated, high-throughput
sample preparation for proteins in a 96-well filter plate by using vacuum pressure without
centrifugation or transfer of the filter plate (4-5 hrs before digestion).12, 17 In this paper, we
modified this approach for metabolite-protein reaction studies by first using enzyme-coated
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magnetic beads to generates metabolites from a test chemical and then achieving buffer-exchange,
denaturation, reduction, and alkylation on a filter plate under vacuum to decrease preparation time
to ~2 hrs before digestion (Scheme 3.1).
Acetaminophen (APAP), a common analgesic, 18 was chosen to investigate drug-induced
protein damage, a leading cause of acute liver failure in APAP users.19 After being absorbed by
the gastrointestinal tract, most acetaminophen is converted to nontoxic glucuronide
(acetaminophen-gluc)

and

sulfate

(acetaminophen-sulf)

metabolites

by

UDP-

glucuronosyltransferases and sulfotransferases. However, 5-9 % of acetaminophen is oxidized to
N-acetyl-p-benzoquinoneimine (NAPQI) catalyzed by cytochrome P450 (cyt P450) enzymes.20,21
Usually, NAPQI is rapidly detoxified by glutathione (GSH), but in situations of GSH deficiency,
such as acetaminophen overdose or long-term use, excess NAPQI reacts with cysteine residues in
proteins, causing cell death and toxicity in liver.22,23 Human glutathione S-transferase pi (hGSTP),
the most effective enzyme catalyzing GSH conjugation with electrophiles, is one of the binding
target proteins for excess NAPQI. 24 - 26 We previously identified and detected hGSTP-NAPQI
adducts by using magnetic beads (MBs) coated with cyt P450 2E1 as bioreactors.27 In the present
paper, we extend this approach to multiple organ microsomal and supersomal enzyme sources to
evaluated relative amounts of NAPQI-GSH conjugate. The chemically modified positions of
NAPQI on hGSTP were identified, and relative amounts of reacted peptides were compared using
a in a 96 well plate sample workup format developed for LC-MS/MS analysis (Scheme 3.1). All
four cysteines (Cys-14, Cys-47, Cys-101, Cys-169) in hGSTP were found to react with NAPQI
for the first time, and form 3-(cysteine-S-yl)-acetaminophen adducts. Liver and lung microsomes
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and CYP1A2 supersome were the most effective enzyme sources for bioactivation of
acetaminophen and damage to hGSTP.

Scheme 3. 1 Bioreactor magnetic beads in a 96-well plate followed by sample treatment and LCMS/MS sequencing to determine modification sites and quantifying relative amounts of

modifications. (A) Magnetic beads coated with cyt P450 enzymes coupled to NADPH
regeneration in a 96-well plate to convert APAP to NAPQI that reacted with hGSTP. (B)
Solutions of modified hGSTP were separated from MBs and transferred to 96-well filter plate.
(C) Modified hGSTP was reduced and alkylated. (D) Modified hGSTP was digested, and
peptides were filtered down to a new plate. (E) LC-MS/MS analysis. The center panel shows a
96-well plate with a possible experimental reaction plan.
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3.3 Experimental Section
3.3.1 Chemicals and Materials
Carboxylated magnetic beads (MB, 1 µm diam., 20 mg/mL) were from Polysciences, Inc.
Glutathione S-transferase (GST) from human placenta was from Sigma-Aldrich. PierceTM trypsin
protease, PierceTM Glu-C protease, PierceTM chymotrypsin protease (TLCK treated) were from
ThermoFisher Scientific. Reduced glutathione (GSH), acetaminophen, glucose 6-phosphate (G6P),
glucose 6-phosphate dehydrogenase (G6PDH), nicotinamide adenine dinucleotide phosphate
(NADP+), urea, dithiothreitol (DTT), iodoacetamide (IAA), poly(diallyldimethylammonium
chloride) (PDDA), poly(sodium 4-styrenesulfonate) (PSS), myoglobin from horse heart were from
Millipore Sigma. Human Liver microsome (HLM), human lung microsome (HLuM), human
kidney microsome (HKM), and human intestine microsome (HIM) were purchased from Sekisui
XenoTech, LLC. Human supersomes 2A6, 3A5, 3A4, 2E1 (Cytochrome P450 + Cytochrome c
Reductase + Cytochrome b5) and human supersomes 1A2, 1B1 (Cytochrome P450 + Cytochrome
c Reductase) were from CORNING. Greiner 96 well plates, polypropylene was from Millipore
Sigma. AcroPrep advance 96 well filter plates for ultrafiltration, OmegaTM membrane 3K MWCO
was from Pall corporation.
3.3.2 Magnetic Beads Bioreactor Assembly
40 µL of magnetic particles was dispersed in 160 µL of 10 mM Tris buffer (pH 7.4, 10 mM
NaCl). 200 µL PDDA (2 mg/mL, 50 mM NaCl) was added drop wisely followed by a 20 min
assembly to coat the negative charged surface with positively charged polycations. The magnetic
particles are pulled towards the magnet. Then, the supernatant was discarded, particles were
washed with Tris buffer twice to remove loosely bound polycations, and dispersed into 200 µL
Tris buffer. The same assembly and wash steps were repeated for polyanion PSS (3 mg/mL, 50
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mM NaCl) and human microsomes or supersomes film growth. The final architecture on the
magnetic bioreactors was MP/PDDA/PSS/PDDA/Microsome or Supersome.
3.3.3 Metabolite Formation
The magnetic bioreactors were incubated with 1 mM acetaminophen, 1 mM GSH, and
NADPH regeneration system (10 mM G6P, 1 mM NADP+, 1 U/mL G6PDH enzyme, 1 mM MgCl2)
in a total volume of 200 µL Tris buffer. After incubation at 37 C for 1h, the reaction was
terminated by magnetic separation. The solutions were transferred to 96-well OmegaTM membrane
3K MWCO filter plate, filtered under vacuum, and spiked with 0.14 µM of N2-benzolyguanosine
as an internal standard before LC-MS/MS analysis. All reactions were done in triplets.
3.3.4 Protein Adducts Formation
The magnetic bioreactors were incubated with 1 mM acetaminophen, 100 µg pretreated
hGSTP, 2 mM DTT and NADPH regeneration system (10 mM G6P, 1 mM NADP+, 1U/mL
G6PDH enzyme, 1 mM MgCl2) in a total volume of 200 µL Tris buffer. After incubation at 37 C
for 12h, the reaction was terminated by magnetic separation. The solutions were transferred to 96well OmegaTM membrane 3K MWCO filter plate. Control experiment was done in the same
condition without adding acetaminophen. All reactions were done in triplets.
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3.3.5 Sample Preparation

Scheme 3. 2 High-throughput sample preparation steps for damage protein analysis.
All the sample treatments were done under vacuum. Protein denaturation, disulfate group
reduction and thiol group alkylation were achieved while solutions were passing through the filter
membrane. The vacuum was set at – 15 inHg, and the solution took 30 min to pass through the
filter membrane. A 96-well plate cover was put under the plate filter to collect the waste. Firstly,
the samples were washed with 100 µL 50 mM ammonium bicarbonate (pH 8.5). 3 µg of horse
heart myoglobin was added to each well as an internal standard. Proteins denaturation and
reduction were carried out by adding 100 µL of 8 M Urea and 20 mM DTT. The free thiol group
on cysteine residues were then alkylated by adding 100 µL of 20 mM IAA in dark. The samples
were washed twice with 100 µL ammonium bicarbonate, then a new 96-well plate was changed
under the filter plate. The samples were digested by MS grade trypsin or chymotrypsin or Glu-C
in a protease/protein (w/w) ratio of 1:25 for 16 hrs. The digestion was stopped by adding 4 µL of
10 % formic acid. The digested peptides were filtered out through the filter plate for LC-MS/MS
analysis (Scheme 3.2).
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3.3.6 HPLC-MS/MS

LC-MS/MS analysis was done on a Thermo Scientific Dionex Ultimate 3000 UHPLC
system interfaced to a Thermo Scientific TSQ Quantiva triple quadrupole mass spectrometer. For
the analysis of metabolites, the samples were separated on a C18 reversed phase analytical column
(Hypersil GOLD, 0.3 × 150 mm, 3 µm, Thermo Scientific) with gradient elution (Table 3.1). The
metabolites identification was done in the product ion scan mode with collision energy 20 V for
GSH-acetaminophen (m/z 457.2). Multiple reaction monitoring (MRM) mode was used to
quantify the metabolites formation. The mass transitions were listed in Table 3.2. Key parameters
of MS instrument were set as ion source type = H-ESI , spray voltage = 3800 V, sheath gas = 15
Arb, aux gas = 7 Arb, sweep gas = 4 Arb, ion transfer tube temperature = 300 C, vaporizer
temperature = 30 C. MRM properties were set as cycle time = 1 s, Q1 resolution (FWHM) = 0.7,
Q3 resolution (FWHM) = 0.7, CID gas = 1.5 mTorr.
Table 3. 1 UHPLC gradient used for metabolite and tryptic peptide identification and quantitation.
Metabolite separation gradient
Time
(min)

Flow

Peptide separation gradient

%B

Time

(µL/min)

(min)

Flow

%B

(µL/min)

0

6

1

0

15

1

7

6

1

7

15

1

16

6

50

19

15

30

16.5

6

90

19.5

15

90

21

6

90

21

15

90

21.5

6

1

21.5

15

1

25

6

1

25

15

1
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Table 3. 2 MRM transitions and parameters used in the metabolite and peptide quantification.
Metabolites

CE, V

Mass transition, m/z

Role

NAPQI-GSH

18

457.2→328.3

Quantitation

20

457.2→382.2

Confirmation

28

388.1→238.1

Quantitation

35

388.1→256.1

Confirmation

Peptides

CE, V

Mass transition, m/z

Role

CAALR

12.4

295.7→359.2 (y3)

Quantitation

12.4

295.7→430.3 (y4)

Confirmation

13.9

341.7→359.2 (y3)

Quantitation

13.9

341.7→430.3 (y4)

Confirmation

21.6

568.8→705.4 (y6)

Quantitation

21.6

568.8→542.3 (y5)

Confirmation

23.2

614.8→705.4 (y6)

Quantitation

23.2

614.8→542.3 (y5)

Confirmation

23.9

636.3→716.4 (y6)

Quantitation

23.9

636.3→910.5 (y8)

Confirmation

13

313.7→182.1 (y1)

Quantitation

13

313.7→445.2 (b3)

Confirmation

N2benzolyguanosine

CAALR

ASCLYGQLPK

ASCLYGQLPK

LFTGHPETLEK

RCKY
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RCKY

KKHGTVVL

VLAPGCLD

VLAPGCLD

IAAKYKE

14.6

359.7→182.1 (y1)

Quantitation

14.6

359.7→537.3 (b3)

Confirmation

17.3

441.3→625.4 (y6)

Quantitation

17.3

441.3→753.5 (y7)

Confirmation

16.9

422.7→213.2 (b2)

Quantitation

16.9

422.7→561.2 (y5)

Confirmation

18.2

468.7→213.2 (b2)

Quantitation

18.2

468.7→653.3 (y5)

Confirmation

16.3

411.7→638.4 (y5)

Quantitation

16.3

411.7→439.2 (y3)

Confirmation

For peptides separation, a Jupiter C18 column (0.5 × 150 mm, 5 µm, Phenomenex) in
gradient elution (Table 3.1) was used. In both separation, 99 % water, 1 % ACN (0.1 % formic
acid) was used as solvent A and 99 % ACN, 1 % water (0.1 % formic acid) was used as solvent B.
The adducted peptide identification was done in the product ion scan mode with collision energy
14 V for adducted peptide 14-18 (m/z 341.7), 23 V for adducted peptide 45-54 (m/z 614.8), 20 V
for adducted peptide 100-103 (m/z 359.7), 21 V for adducted peptide 164-171 (m/z 468.7).
Multiple reaction monitoring (MRM) mode was used to quantify the adducted peptides. An opensource bioinformatics tool, Skyline28, was used to generate the mass transition list for MRM. All
mass transitions are listed in Table 3.2. The MRM data were then imported back to Skyline to
obtain peak areas of peptides. Key parameters of MS instrument were set as ion source type = H60

ESI, spray voltage = 3900 V, sheath gas = 20 Arb, aux gas = 7 Arb, sweep gas = 2 Arb, ion transfer
tube temperature = 300 C, vaporizer temperature = 30 C. MRM properties were set as cycle time
= 1s, Q1 resolution (FWHM) = 0.7, Q3 resolution (FWHM) = 0.7, CID gas = 1.5 mTorr.
3.4 Results
The protein hGSTP was reacted with acetaminophen in microwells catalyzed by magnetic
beads bioreactor coated with different cyt P450 enzyme sources. Ten different CYP enzyme
sources were used, four microsomal enzymes including human liver microsomes (HLMs), human
lung microsomes (HLuMs), human kidney microsomes (HKMs), and human intestine microsomes
(HIMs); four CYP supersomes that contain major enzymes in specific organs, including CYP1A2
(liver), CYP2A6 (lung), CYP1B1 (kidney), and CYP3A5 (liver and intestine);29,30,31 two other
CYP supersomes that are responsible for acetaminophen metabolism, CYP2E1 and
CYP3A4.27,32,33 The bioactivation of acetaminophen was driven by NADPH regeneration system
dissolved in solution to form its metabolite NAPQI, which then reacted with hGSTP in solution.
The modified hGSTP was isolated from bioreactor MBs by a magnet, then denatured, reduced,
alkylated and digested on a filter plate. The modified positions of NAPQI on hGSTP was located
by LC-MS/MS. Fragmentation of protease digested peptides typically show cleavage of peptide
bonds, enabling sequencing of the peptide and identification of modified amino acids.34-36 The
relative amount of metabolite formation and modified peptides were also evaluated. (Scheme 3.1)
3.4.1 Metabolite Formation
The formation of NAPQI was identified by adding GSH in solution to form NAPQI-GSH
conjugate. Different cyt P450 enzymes were deposited onto magnetic beads to form bioreactor
beads by using alternate electrostatic layer-by-layer assembly in order to catalyze metabolite
formation.37,38 GSH in the incubation system was used to trap the reactive metabolite NAPQI
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following generation, and the bioreactor beads were removed by a magnet. Product ion spectrum
of NAPQI-GSH conjugate at m/z 457.2 shows typical fragmented ion patterns at m/z 328.3, 382.2,
and 182.1 corresponding to protonated fragment ions as shown in Figure 3.1A.

Figure 3. 1 LC-MS/MS results for NAPQI-GSH conjugate. (A) Product ion spectrum of
NAPQI-GSH conjugate at m/z 457.2 with collision energy 20 V; (B) Extracted ion
chromatogram (XIC) for MRM mass transition m/z 457.2 to m/z 328.3.
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Figure 3. 2 The representative MRM chromatograms containing two transitions of each
molecule for quantitation purpose. (A) NAPQI-GSH conjugate; (B) internal standard N2benzolyguanosine.
Extracted ion chromatography (XIC) for MRM mass transition m/z 457.2 to 328.3 shows
the NAPQI-GSH conjugate eluted at 13.7 min (Figure 3.1B). Detection of the NAPQI-GSH
conjugate confirmed NAPQI metabolite formation.27,39
Relative amounts of NAPQI-GSH conjugates were measured by LC-MRM using N2benzolyguanosine as an internal standard (Figure 3.2). Detailed MRM mass transitions are listed
in Table 3.2. Figure 3.4 shows relative amounts of NAPQI-GSH conjugate obtained for different
enzyme sources. Results were normalized to the amounts of enzymes on the magnetic beads
(estimated by bicinchoninic acid (BCA) assay with Micro BCA Protein Assay, Figure 3.3),
concentration of acetaminophen used, and time of reaction. The order of bioactivation activity of
different organ microsomes was found as HLM ≈ HLuM > HIM > HKM. The order of
bioactivation activity of different cyt P450 supersomes was 1A2 > 2E1 > 3A5 > 3A4 > 2A6 > 1B1.
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Figure 3. 3 Micro BCA protein assays for (A) standard human liver microsome (HLM), (B)
standard cytochrome P450 1A2.

Figure 3. 4 NAPQI-GSH conjugate formation with different enzymes. Relative amounts of
NAPQI-GSH conjugate {µg of protein}-1, {mM acetaminophen}-1, h-1 formed as ratios of area
under NAPQI-GSH peak to that of internal standard after incubation for 1hr at 37 C.
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3.4.2 Protein Adduct
To investigate metabolite-protein adducts, enzyme-bioreactor magnetic beads were
incubated with acetaminophen and hGSTP in solution. The reaction was terminated by removing
bioreactors with a magnet, leaving adducted and non-adducted hGSTP in solution. The solution
was transferred to a new 96-well filter plate for denaturation, reduction, alkylation, and protease
digestion. The purpose of alkylation is to protect the free sulfhydryl groups from forming disulfide
bonds again. Horse heart myoglobin was added before denaturation as an internal standard. Three
proteases, trypsin, chymotrypsin and Glu-C were used to detect all modified cysteines in hGSTP.

Figure 3. 5 Product ion spectrum of (A) NAPQI-adducted peptide CAALR with m/z 341.7;
(B) NAPQI-adducted peptide ASCLYGQLPK with m/z 614.8 by trypsin digestion. The b
or y ions reflecting NAPQI modification are indicated in red.
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Figure 3. 6 Product ion spectrum of (A) unadducted peptide CAALR with m/z 295.7; (B)
unadducted peptide ASCLYGQLPK with m/z 568.8.

Figure 3. 7 Extracted ion chromatograms (XIC) for NAPQI-adducted and unadducted
CAALR, NAPQI-adducted and unadducted ASCLYGQLPK, and peptide LFTGHPETLEK
from internal standard by trypsin digestion.
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The mass of a NAPQI-adducted peptide will increase by 149.048, which is the monoisotopic
mass of NAPQI. Adducted peptides CAALR representing position 14 to 18 and ASCLYGQLPK
at position 45 to 54 in trypsin digested hGSTP were found. The MS/MS spectrum of adducted
peptide CAALR with m/z 341.7 (Figure 3.5A) shows unchanged y1, y2, y3, y4 ions, and increased
b2 and b3 ions, which indicates Cys-14 was adducted. The MS/MS spectrum of adducted peptide
ASCLYGQLPK with m/z 614.8 (Figure 3.5B) shows increased b3, b5, b6 ions, also increased y8,
y9 ions indicating adducted Cys-47. The unadducted peptide 14-18 with m/z 295.7 and 45-54 with
m/z 568.8 were found in unreacted control samples. The MS/MS spectra of unadducted peptide
14-18 and 45-54 are shown in Figure 3.6.

Figure 3. 8 The representative MRM chromatograms containing two transitions for a single
tryptic peptide for quantitation purpose.
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LC-MRM MS conditions were optimized so that the adducted and unadducted peptides were
well separated to provide a good basis for quantitation (Figure 3.7). Two MRM transitions were
used to identify each peptide and the one with larger peak area was used for quantitation (Figure
3.8, Table 3.2). M/z transitions 341.7 to 359.2, 295.7 to 359.2 were used for adducted and
unadducted CAALR; m/z transitions 614.8 to 705.4, 568.8 to 705.4 were used for adducted and
unadducted ASCLYGQLPK; m/z 636.3 to 716.4 was used for internal standard LFTGHPETLEK.
Relative amounts of adducted peptides were estimated as ratio of peak area of adducted peptide to
that of internal standard divided by ratio of peak area under unadducted peptide to that under
internal standard. Figure 3.9A shows the relative amounts of adducted peptide 14-18 containing
Cys-14 with different enzyme sources. Results were normalized by the amounts of enzyme
proteins on the magnetic beads (estimated by Micro BCA Protein Assay, Figure 3.4), concentration
of acetaminophen used, and time of reaction. The order of bioactivation activity of different organ
microsomes was found as HLM > HLuM ≈ HKM > HIM. The order of bioactivation activity of
different supersomes was 1A2 > 2E1 > 3A4 > 2A6 > 3A5 > 1B1. For relative amount of adducted
peptide 45-54, the order of bioactivation activity of different enzymes was found as similar with
adducted peptide 14-18, but with 3A5 larger than 3A4 and 2A6.

Figure 3. 9 NAPQI-adducted peptides formation with different enzymes. Relative amounts
of NAPQI-adducted peptide (A) CAALR and (B) ASCLYGQLPK {µg of protein}-1, {mM
acetaminophen}-1, h-1.
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Chymotrypsin was used to detect NAPQI modification on Cys-101. Figure 3.10A shows
extracted ion chromatograms (XIC) for adducted and unadducted peptides 100-103, and internal
standard KKHGTVVL. The MS/MS spectrum of adducted peptide 100-103 (RCKY) with m/z
359.7 (Figure 3.10B) shows unchanged y1, y2, b1 ions, and increased b2, b3, and y3 ions, which
indicates Cys-101 was adducted. The unadducted peptide 100-103 with m/z 313.7 was found in
unreacted control samples. The MS/MS spectra of unadducted peptide 100-103 are shown in
Figure 3.11. Relative amounts of adducted peptide 100-103 was estimated by peak areas under
MRM peaks of adducted and unadducted peptides similarly with peptide 14-18. Detailed mass
transitions were listed in Table 3.2 and MRM chromatograms in Figure 3.12. The order of
bioactivation activity of different organ microsomes was found as HLM ≈ HLuM > HKM > HIM.
The order of bioactivation activity of different supersomes was 1A2 > 3A4 > 2E1 ≈ 2A6 >3A5 >
1B1 (Figure 3.13A).

Figure 3. 10 (A) Extracted ion chromatograms (XIC) for NAPQI-adducted and unadducted
RCKY, and peptide KKHGTVVL from internal standard; (B) Product ion spectrum of
NAPQI-adducted peptide RCKY with m/z 359.7 by chymotrypsin digestion.

69

Figure 3. 11 Product ion spectrum of (A) unadducted peptide RCKY with m/z 313.7; (B)
unadducted peptide VLAPGCLD with m/z 422.8.

Glu-C was used to detect NAPQI modification on Cys-169. Figure 3.14A shows extracted
ion chromatograms (XIC) for adducted and unadducted peptides 164-171, and internal standard
IAAKYKE. The MS/MS spectrum of adducted peptide 164-171 (VLAPGCLD) with m/z 468.7
(Figure 3.14B) shows unchanged y1, y2, b2, b3, and b5 ions, and increased y3, y5, y6, and b6 ions,
which indicates Cys-169 was adducted. The unadducted peptide 164-171 with m/z 422.7 was
found in unreacted control samples. The MS/MS spectra of unadducted peptide 164-171 are shown
in Figure 3.11B. Relative amounts of adducted peptide 164-171 was estimated by peak areas under
MRM peaks of adducted and unadducted peptides similarly with peptide 14-18. Detailed mass
transitions were listed in Table 3.2 and MRM chromatograms in Figure 3.15. The order of
bioactivation activity of different organ microsomes was found as HLuM > HLM > HKM ≈ HIM.
The order of bioactivation activity of different supersomes was 1A2 > 2E1 > 2A6 > 3A4 > 3A5 >
1B1 (Figure 3.13B).
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Figure 3. 12 The representative MRM chromatograms containing two transitions for a single
Chymotrypsin digested peptide for quantitation purpose.

Figure 3. 13 NAPQI-adducted peptides formation with different enzymes. Relative amounts of
NAPQI-adducted peptide (A) RCKY and (B) VLAPGCLD {µg of protein}-1, {mM
acetaminophen}-1, h-1 formed as ratio of area under NAPQI-adducted peptide peak to that of
internal standard over ratio of area under unadducted peptide peak to that of internal standard in
control.
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Figure 3. 15 NAPQI-adducted peptides formation with different enzymes. Relative amounts of
NAPQI-adducted peptide (A) RCKY and (B) VLAPGCLD {µg of protein}-1, {mM
acetaminophen}-1, h-1 formed as ratio of area under NAPQI-adducted peptide peak to that of
internal standard over ratio of area under unadducted peptide peak to that of internal standard in
control.

Figure 3. 14 The representative MRM chromatograms containing two transitions for a single GluC digested peptide for quantitation purpose.
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3.5 Discussion
Results above demonstrate a new, cell-free in vitro assay that metabolizes test compounds
using a range of desired metabolic enzymes to produce reactive metabolites that react with proteins
and enables protein sample preparation for analysis by LC-MS/MS. The magnetic bead bioreactors
coated with metabolic enzymes facilitate investigation of a wide range of cyt P450s enzymes and
greatly simplify separation of reacted proteins from the enzyme. The sample preparation method
using 96-well filter plate under vacuum shortens the sample preparation time and avoids transfer
of the sample plate. This method is simple, fast, high-throughput, and facilitates mapping of
modified positions on proteins.
All the enzyme sources used led to the same metabolite formation, but at different rates. The
largest amount of NAPQI was formed when human liver microsomes and human lung microsomes
were used (Figure 3.3), which correlates with liver as the major damage site in acetaminophen
overdose. 40 Human kidney and intestine microsomes had low bioactivation rates (Figure 3.3).
Among the supersomes used, cyt P450 1A2 produced the largest amount of NAPQI, followed by
cyt P450 2E1 and 3A5. cyt P450s 1A2, 2E1, and 3A5 are strongly expressed in human liver31,41
and our results are fully consistent with reports that cyt P450s 1A2 and 2E1 are major factors for
acetaminophen bioactivation in humans.26, 42 Cyt P450 3A4 provided moderate bioactivation,
while activities of cyt P450s 2A6 and 1B1 were quite low.
Results in Figure 3.5 show that two adducted positions, Cys-14 and Cys-47 on hGSTP were
observed by using trypsin digestion. The adduction by NAPQI at Cys-47 is consistent with other
reports, 43-45 and Cys-47 is highly reactive toward electrophiles due to its relatively low pKa and
accessibility.46,47 Adducted Cys-101 and Cys-169 were not found by using trypsin as digestion
protease. With trypsin digestion, Cys-101 is expected to exist as a dipeptide CK, which may have
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low retention on reverse phase chromatography. The peptide containing Cys-169 consists of 42
amino acids from residue 141 to 182, which is too large to be detected.44 Chymotrypsin and GluC were used to detect modifications on Cys-101 (Figure 3.10) and Cys-169 (Figure 3.14).
Modifications of NAPQI on Cys-101 was confirmed in the previous report43, and on Cys-169 was
reported for the first time.
The results of relative amounts of NAPQI adducted peptides showed CYP1A2 gave the
highest adducted peptide formation, followed by cyt P450 2E1 (Figure 3.9, 3.13). Among
microsomes, human liver microsomes gave more adducted peptides than others. Results are
consistent with amounts of NAPQI metabolite formation (Figure 3.3), i.e., the more metabolite
formed, the more adducted peptide formation. Also, results confirm cyt P450 1A2 and 2E1 as
major enzymes responsible for acetaminophen liver failure.26,42
3.6 Conclusion
We describe above a new high-enzyme throughput sample preparation method coupled with
enzyme-coated magnetic bead bioreactors that facilitates bioactivation of drugs to reactive
metabolites and reaction with proteins to characterize specific damage to the proteins. All 4
cysteines in hGSTP (Cys-14, Cys-47, Cys-101, and Cys-169) reacted with the acetaminophen
metabolite. This new methodology is suitable for organ-specific analysis of protein damage by
metabolites of drugs and other chemicals. The method provides exact sites and relative amounts
of adduct formation compared with traditional radioisotope or immunological techniques, and also
identifies the most active enzymes for active metabolite generation.
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Chapter 4 LC/MS Quantitation of Biotherapeutic Monoclonal Antibody Glycoforms
4.1 Abstract
Therapeutic biotechnology products, such as monoclonal antibodies (mAbs) are subject to
reactions during cell culture processing, purification, and storage process. Multiple product
variants are formed which results in heterogeneity of mAbs. N-glycosylation is one of the most
common post-translational modifications. Glycan structures attached on the CH2 domain of the Fc
region of immunoglobulin G (IgG) are essential for its functionalization, but their effects on
clearance is less clear. Clearance of therapeutic antibodies is important as it impacts efficacy. Here,
we are developing quantitative methods to investigate the impact of Fc glycans on the clearance
of a therapeutic humanized IgG1 monoclonal antibody by LC-MS/MS. The methods consisted of
an immunocapture purification followed by tryptic digestion and LC-MS/MS analysis of surrogate
peptides associate with glycosylation sites. Two methods were developed and compared, one is
establishing calibration curves with glycopeptides intensities versus concentrations without
internal standards; the other one is dimethyl labelling of tryptic peptides with either d(2)-13C or
d(0)-formaldehyde and establishing calibration curves with heavily labelled peptides as internal
standards. Both methods gave similar linearity, LLOQ of dimethyl labelled method was two times
higher than the unlabeled method. These methods allowed us to assess in vivo changes of all
glycopeptides over the duration of a preclinical pharmacokinetic study in cynomolgus monkeys.
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4.2 Introduction
Monoclonal antibodies (mAbs) are emerging therapeutic products in the pharmaceutical
industry for the past decades.1-3 Post-translational modifications occur naturally during antibody
biosynthesis, purification, and storage process, which results in multiple variants of antibodies.4
Some variants, such as deamidation, oxidation, and glycosylation, have been reported to have
significant impact on antibody biological activities. 5 -7 Those modifications are considered as
critical quality attributes, which must be limited to appropriate level to ensure the drug safety and
efficacy.
Glycosylation is one of the most common post-translational modifications of therapeutic
antibodies. Different levels of terminal galactose residues with fucose core (G0F, G1F, and G2F
where G represents the number of galactose, F is the fucose core) and some high mannose
structures are usually attached at the Fc site of recombinant antibodies which are expressed using
Chinese hamster ovary tissue culture.8-10 The half-life of antibodies in serum is regulated by Fc
receptor, which is not influenced by the presence of different glycoforms. 11 , 12 But mannose
receptors have the ability to clear glycoproteins with terminal Mannose.13,14 Thus, the antibodies
with high mannose structures may clear faster, which would affect the antibody drug efficacy. 15
Glycosylation is considered as one of the quality attributes, which should be assessed in preclinical
and clinical samples to ensure the drug safety and efficacy.16 In order to check the clearance rate
of different glycoforms, quantitative methods for glycoforms should be developed, and the
clearance of various glycoforms should be assessed in preclinical and clinical samples to provide
quality attributes criticality in the biopharmaceutical manufacturing process.
Mostly used method for glycoanalysis is released glycans, in which the glycans are released
from all the glycoproteins, and each glycoform is monitored. 17 - 19 By using this method,
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information about the originating proteins or the glycosylation sites can not be obtained.20 Another
commonly used method is intact protein analysis, in which the intact protein containing glycans is
analyzed. The limitation of this method is that the glycoforms with low abundance could not be
detected.21 The last method that incorporates the originating proteins and the glycosylation sites is
analysis of glycopeptides from the Fc region. This method is restricted to relative quantitation due
to lack of isotopic labeled glycopeptides. The level of a glycopeptide is calculated as response of
the glycopeptide divided by sum of responses of all glycopeptides from the same peptide.22
Herein, absolute quantitative methods for therapeutic antibody IgG1 glycopeptides were
developed using LC-MS/MS. Dimethyl labelling was performed at peptide level after trypsin
digestion, the labelled glycopeptides were used as internal standards. These developed methods
can be employed to investigate the clearance of different glycoforms using cynomolgus monkey
plasma samples from a preclinical pharmacokinetic study.
4.3 Experiment Section
4.3.1 Chemicals and Materials
Monoclonal antibody IgG1 was a proprietary experimental biotherapeutic of Boehringer
Ingelheim Pharmaceuticals and produced in-house. The goat anti-human IgG was purchased from
Abcam. Streptavidin magnetic beads (1 µm dia.), TPCK trypsin, and EZ-Link Sulfo-NHS-LC
Biotinylation kit were obtained from Thermo Scientific. RapiGest SF was purchased from Waters.
All other chemicals, reagents, and buffer solutions were from MilliporeSigma.
4.3.2 Biotinylation of anti-human IgG
Biotinylation of goat anti-human IgG was performed using an EZ-Link Sulfo-NHS-LC
Biotinylation kit. Anti-human IgG solution (1 mg/mL) was incubated with 20-fold molar excess
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of biotin at room temperature for 1 hr. Excess biotin was removed by Zeba spin desalting columns.
HABA assay was used to measure the level of biotin incorporation after removing all traces of
non-reacted and hydrolyzed biotinylation reagent. The typical biotin corporation was 2-7 biotins
per anti-human IgG. Then, the biotinylated was diluted to 0.1 mg/mL and stored in -80 C prior to
use.
4.3.3 Immunoaffinity Capture
Stock concentration of mAb IgG1 was 10.21 mg/mL. A series of 50-100,000 ng/mL spiking
calibration standards were prepared in cynomolgus monkey plasma, the QC samples were prepared
in the concentrations of 300, 2500, and 75000 ng/mL and stored at -80 C prior to use. The
immunocapture procedure is similar as previously reports.23,24 20 µL of plasma samples, 75 µL of
biotinylated anti-human IgG, and 450 µL of Tris buffered saline (25 mM Tris, 150 mM NaCl, pH
7.2) with 0.1 % Tween 20 (TBS-T) were pipetted into a 96-deep-well polypropylene plate. The
plate was incubated at room temperature for 2 hrs. A 50 µL aliquot of freshly prepared 5 mg/mL
magnetic beads were added to each sample and the plate was incubated for another 1.5 hrs. The
beads were separated, washed three times with 300 µL TBS-T, once with 300 µL water, and then
eluted with 150 µL of 25 mM HCl on a KingFisher Flex bead handler. (Scheme 4.1)
4.3.4 Trypsin Digestion
To the immunocapture eluent, or neat IgG1 solution (30 µg in 150 µL 25 mM HCl), 20 µL
of 1M Tris-HCl (pH 8.0) was added to neutralize the solution. 10 µL of 0.1% RapiGest and 10 µL
of 100 mM Tris(2-carboxyethyl)phosphine (TCEP) in 100 mM ammonium bicarbonate were
added and followed by incubation at 60 C for 1hr. 5 µL of 200 mM iodoacetamide in 100 mM
ammonium bicarbonate was added to alkylate the free thiol groups at room temperature for 30 min
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Scheme 4. 1 Immunocapture LC-MS Assay Workflow.
in dark. 10 µL of 6 µg/ µL trypsin was added to each sample and the plate was incubated at 37 C
overnight. Digestion was quenched by adding 5 µL of 20 % trifluoroacetic acid (TFA). The
samples were mixed for 40 min at 37 C, then centrifuged at 3800 rpm for 10 min prior for LC/MS
analysis.

4.3.5 Dimethyl Labelling
After trypsin digestion, 20 µL of NaBH3CN and 20 µL of d(0)-formaldehyde were added to
each standard and QC sample well for d(0)-dimethyl labelling. 20 µL of NaBD3CN and 20 µL of
d(2)-13C-formaldehyde were added to neat digestion sample well for d(2)-13C-dimethyl labelling.
The plate was incubated and shaken at room temperature for 2 hrs. The resultant reaction mixture
in each well was then acidified by adding 10 µL of 20 % TFA. 5 µL of the d(2)-13C-dimethyl
labelled sample was then spiked into each d(0)-dimethyl labelled samples as internal standard. The
sample plate was then centrifuged and analyzed using UPLC-MS/MS.
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4.3.6 LC-MS Analysis
A Waters ACQUITY UPLC coupled with AB Sciex 6600 triple TOF mass spectrometer was
used for glycopeptide identification. Chromatographic separation was performed using ACQUITY
UPLC Peptide BEH C18 column (1mm × 50 mm, 1.7 µm, 300 Å) operated at 50 C. Mobile phases
consisted of (A) water with 0.1 % formic acid and (B) acetonitrile with 0.1 % formic acid running
at a flow rate of 300 µL/min. The LC gradient was 1 % to 10 % B over 6 min, then to 95 % B over
0.5 min, and back to 1 % B at 10 min. The mass spectrometer was operated in a positive
electrospray ionization mode. Key instrument parameters were as follow: +5500 V electrospray
voltage, 350 ion source temperature, ion source gas 1 with 80, ion source gas 2 with 20, curtain
gas 35.
A Waters ACQUITY UPLC coupled with AB Sciex 6500 + triple quadrupole mass
spectrometer was used for glycopeptide quantitation. Chromatographic separation was performed
using ACQUITY UPLC Peptide BEH C18 column (1mm × 50 mm, 1.7 µm, 300 Å) operated at
50 C. Mobile phases consisted of (A) water with 0.1 % formic acid and (B) acetonitrile with 0.1 %
formic acid running at a flow rate of 15 µL/min. The LC gradient was 6 % to 25 % B over 6 min,
then to 95 % B over 2 min, and back to 6 % B at 10 min. The mass spectrometer was operated in
a positive electrospray ionization mode. Key instrument parameters were as follow: +5500 V
electrospray voltage, 200 ion source temperature, ion source gas 1 with 45, ion source gas 2 with
35, curtain gas25, 12 collision gas units, and unit resolution on both Q1 and Q3. Multiple reaction
monitoring (MRM) mode was conducted for glycopeptide quantitation.

84

4.4 Results
Methods for the absolute quantitation of therapeutic antibody immunoglobulin G1
glycoforms were developed using MRM on a QqQ-MS. The synthesized IgG1 was used to study
the behavior of IgG 1 glycopeptides in MRM experiments and develop methods for the
quantitative analysis of its glycoforms. The methods were then applied to a pooled monkey plasma
sample to estabolish calibration curves for each glycopeptide in order to assess in vivo changes of
glycoforms over duration of a preclinical pharmacokinetic study in cynomolgus monkeys. The
collison induced dissociation (CID) behavior of the tryptic glycopeptides was first studied using
TOF-MS. Based on these results, MRM transitions were developed on the QqQ-MS, and the
instrument parameters were optimized to get the best sensitivity for each glycopeptide. The
abundance of each glycopeptide was calculated by percentage of peak areas under extracted ion
chromatograms (XIC) of glycopeptides. The absolute concentrations of each glycopeptide were
calculated by multiplying the abundance with the concentration of antibody. The calibration curves
of each glycopeptide were plotted using MRM peak areas versus concentrations of glycopeptides.
Using this strategy, all the glycopeptides were monitored and quantified simultaneously.
4.4.1 Identification of glycopeptides
An IgG 1 standard was subjected to trypsin digestion, and the resulting peptides and
glycopeptides were analyzed using LC-triple TOF MS/MS to evalute the fragementation behavior.
The tryptic peptide EEQYNSTYR is the target peptide on Fc region that contains N-glycosylation
site. Figure 4.1 shows the TOF spectra of G0F, G1F, and Mann5 with +2 and +3 charge. The
abundance of each glycopeptide was calculated as ratio between sum of peak areas under XIC of
each isotopic peak for one glycopeptide and sum of peak areas under XIC of all glycopeptides.
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Results are summarized in Table 4.1. Seven glycopeptides were observed in the sample with G0F
(33.1 %), G1F (35 %), Mann5 (15.2 %), G2F (7.8 %), G0 (2.5 %), G1 (1.2 %), G0F-N (5.2 %).

Figure 4. 1 TOF spectra of glycopeptides. (A) G0F, z = +3; (B) G0F, z = +2; (C) G1F, z = +3;
(D) G1F, z = +2; (E) Mann5, z = +3; (F) Mann5, z = +2.
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Table 4. 1 Structure and abundance of observed glycopeptides.

Figure 4. 2 Product ion scan spectra of glycopeptides: (A) MS/MS spectrum of G0FEEQYNSTYR (m/z 878.68, z = +3); (B) MS/MS spectrum of Mann5-EEQYNSTYR (m/z
802.65, z = +3).
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LC-MS analysis with tripleTOF instrument allowed identification of the glycopeptides based
on the accurate mass and the tandem MS. The fragmentation spectra showed the typical glycan
fragment ions, corresponding to the small glycan fragments, including m/z 204.08 (HexNAc),
366.14 (Hex1HexNAc1), 528.19 (Hex2HexNAc1). The MS/MS spectra of two glycopeptides G0F
and Mann5 are shown in Figure 4.2, and the predicted glycan fragments are clearly visible with
high intensities.
Table 4. 2 MRM transitions, optimized CE, DP, and CXP for glycopeptides.
Glycoforms

MRM pairs

CE

DP

CXP

G0F

878.68 → 204.08

20

60

10

G1F

932.70 → 204.08

24

60

20

Mann5

802.65 → 204.08

36

70

10

G2F

986.72 → 204.08

36

60

10

G0

830.00 → 204.08

24

70

10

G1

884.02 → 204.08

28

60

10

G0F-N

810.99 → 204.08

24

60

10

4.4.2 Quantitation of glycopeptides
In the tandem MS spectra of glycopeptides, m/z 204.08 is the most abundant fragmentation
ion. The MRM transitions for all the glycopeptides are their precursor ions to 204.08, which are
listed in Table 4.2. Also, the optimized collision energy (CE), declustering potential (DP), and cell
exit potential (CXP) for each glycopeptide are included in Table 4.2.
The chromatograms for glycopeptides obtained from the MRM transitions are shown in
Figure 4.3. All glycopeptides were eluted from 4.4 to 4.8 min, because the retention was influenced
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mostly by the peptide moiety, the variety of glycoforms on the same peptide will not influence the
retention time a lot.

Figure 4. 3 MRM chromatogram for IgG 1 glycopeptides using UPLC-C18 chromatography.

The absolute quantitation of glycopeptides is hard to be achieved due to the lack of
glycopeptide standards. Here, we calculated the concentrations of each glycopeptide with their
abundance. The calibration curves were constructed by plotting the MRM peak area under each
glycopeptide versus their concentrations, which can be obtained in one single run. Figure 4.4
shows the calibration curves for G0F and Mann5 in monkey plasma. The linear range for G0F is
17 – 33100 ng/mL; Mann5 is 76 – 15200 ng/mL. Figure 4.5 shows the LC-MS chromatograms for
G0F and Mann5 in their LLOQ samples.
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Figure 4. 4 Calibration curves of G0F (A) and Mann5 (B) in monkey plasma.
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Figure 4. 5 LC/MS chromatograms of G0F (A) and Mann5 (B) from LLOQ samples.

Table 4. 3 Method Qualification
Glycoforms

G0F

G1F

Mann5

Calibration standard curve range

17-33100 ng/mL

35-35000ng/mL

76-15200 ng/mL

99, 828, 24825

105, 875, 26250

380, 11400

ng/mL

ng/mL

ng/mL

QC Intra-batch Precision (%CV)

5.3% – 31.1%

4.7% – 26.6%

6.4% – 19.1%

QC Intra-batch Accuracy (%RE)

-9.2% - 19%

-15.7% - 24%

-5.0% – 10.9%

QC Inter-batch Precision (%CV)

15% - 21%

15.6% – 20.3%

13.5% – 14.2%

QC Inter-batch Accuracy (%RE)

-7.1% – 9.5%

-9.8% – 10.4%

0.9% – 2.8%

QC concentrations
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4.4.3 Method Qualification
Three batches of calibration standards, and quality control (QC) samples were ran on the
assay to validate the quality of the method. Three different concentration levels of QC samples
(four duplicates each) were used. The concentrations of QC samples for each glycoform were
calculated based on IgG 1 concentrations and their abundance. There are two QC concentrations
for Mann5 since the concentration of Mann5 in low QC sample is lower than LLOQ. Results for
method qualification are shown in Table 4.3. QC intra-batch precision was calculated as relative
standard deviation of 4 replicated QC samples in one batch. QC inter-batch precision was
calculated as relative standard deviation of 12 QC samples in three batches (6 QC samples for
Mann5). QC intra-batch accuracy was calculated as relative error ((calculated concentration –
exact concentration)/ exact concentration × 100) of 4 replicated QC samples in one batch. QC
inter-batch accuracy was calculated as relative error of 12 QC samples in three batches (6 QC
samples for Mann5).
4.4.4 Dimethyl Labeling at Peptide Level
No internal standards were used in the previous quantitation method due to lack of synthetic
isotopic labeled glycopeptides. Reductive amination of primary amine groups at N-terminal on
tryptic peptides was performed to generate stable isotope labeled internal standards. As shown in
Scheme 4.2, for light labeling, d(0)-formaldehyde and sodium cyanoborohydride were used as the
reagents to add two methyl group on the N-terminal; for heavy labeling, 13C-d(2)-formaldehyde
and sodium cyanoborodeuteride were used as the reagents to add two deuterated methyl groups on
the N-terminal.
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Scheme 4. 2 Reactions of dimethyl labeling.

4.4.5 Identification of Dimethyl Labeled Glycopeptides
Two IgG 1 standards were subjected to trypsin digestion, followed by light and heavy
dimethyl labeling reactions, and the resulting peptides and glycopeptides were analyzed using LCtriple TOF MS/MS to identify dimethyl labeled glycopeptides. Figure 4.6 shows the TOF spectra
of light labeled and heavy labeld G0F (A, B), G1F (C, D), and Mann5 (E, F) with +3 charge, which
indicates the formation of dimethyl labeled glycopeptides.
4.4.6 Quantitation of Dimethyl Labeled Glycopeptides
Light labeling was performed on all calibration standard samples after trypsin digestion.
Heavy labeling was performed on neat IgG 1 solution after trypsin digestion. Finally, same amount
of heavy labeled sample was spiked into each calibration standard samples for LC-MS analysis.
MRM transitions used in the quantitation are listed in Table 4.4. The calibration curves were
constructed by plotting the MRM peak area ratio between light and heavy labeled glycopeptides
versus their concentrations, which can be obtained in one single run. Figure 4.7 shows the LC-MS
chromatograms for G0F and Mann5 in their LLOQ samples. Figure 4.8 shows the calibration
curves for G0F and Mann5 in monkey plasma. The linear range for G0F is 33 – 26480 ng/mL;
Mann5 is 152 – 12160 ng/mL; G1F is 175 – 35000 ng/mL.
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Figure 4. 6 TOF spectra of dimethyl labeled glycopeptides. (A) light labeled G0F, z = +3;
(B) heavy labeled G0F, z = +3; (C) light labeled G1F, z = +3; (D) heavy labeled G1F, z =
+3; (E) light labeled Mann5, z = +3; (F) heavy labeled Mann5, z = +3.
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Table 4. 4 MRM transitions for dimethyl labeled glycopeptides.
G0F

G1F

Mann5

Light Label

887.92 → 204.08

942.13 → 204.08

811.62 → 204.08

Heavy Lable

890.61 → 204.08

944.82 → 204.08

814.30 → 204.08

Figure 4. 7 LC/MS chromatograms of light labeled G0F (A) and Mann5 (B) from LLOQ
samples.
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Figure 4. 8 Calibration curves of G0F (A) and Mann5 (B) in monkey plasma.
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4.5 Conclusion
An absolute quantitative method for various IgG1 glycoforms in vivo was developed and
validated with the linear range 17 – 33100 ng/mL for G0F and 76 – 15200 ng/mL for Mann5.
Dimethyl labelling at peptide N-terminal served as internal standard was developed, with similar
linearity, and 2-5 times lower sensitivities. The methods can be used to analyze clearance rate of
various glycoforms using cynomolgus monkey plasma samples.
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